EP3491384B1 - Zusammensetzungen und verfahren zum schnellen klonen von t-zell-rezeptoren - Google Patents
Zusammensetzungen und verfahren zum schnellen klonen von t-zell-rezeptoren Download PDFInfo
- Publication number
- EP3491384B1 EP3491384B1 EP17837547.3A EP17837547A EP3491384B1 EP 3491384 B1 EP3491384 B1 EP 3491384B1 EP 17837547 A EP17837547 A EP 17837547A EP 3491384 B1 EP3491384 B1 EP 3491384B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- httcr
- seq
- tcr
- cells
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091008874 T cell receptors Proteins 0.000 title claims description 395
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims description 362
- 238000000034 method Methods 0.000 title claims description 89
- 238000010367 cloning Methods 0.000 title claims description 68
- 239000000203 mixture Substances 0.000 title description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 203
- 206010028980 Neoplasm Diseases 0.000 claims description 172
- 239000012634 fragment Substances 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 103
- 239000000427 antigen Substances 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 239000013598 vector Substances 0.000 claims description 77
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 54
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 54
- 201000011510 cancer Diseases 0.000 claims description 54
- 238000010804 cDNA synthesis Methods 0.000 claims description 49
- 239000002299 complementary DNA Substances 0.000 claims description 44
- 108020004635 Complementary DNA Proteins 0.000 claims description 43
- 210000004698 lymphocyte Anatomy 0.000 claims description 33
- 108091093088 Amplicon Proteins 0.000 claims description 32
- 108091008146 restriction endonucleases Proteins 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 238000012408 PCR amplification Methods 0.000 claims description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- -1 Spl7 Proteins 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 102100031780 Endonuclease Human genes 0.000 claims description 6
- 108060002716 Exonuclease Proteins 0.000 claims description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 6
- 102000013165 exonuclease Human genes 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 5
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 5
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 5
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 5
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 claims description 5
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 claims description 5
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 5
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 5
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 5
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 claims description 5
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims description 5
- 102000003735 Mesothelin Human genes 0.000 claims description 5
- 108090000015 Mesothelin Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 5
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 102000000763 Survivin Human genes 0.000 claims description 5
- 108010002687 Survivin Proteins 0.000 claims description 5
- 102000003425 Tyrosinase Human genes 0.000 claims description 5
- 108060008724 Tyrosinase Proteins 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 102000040856 WT1 Human genes 0.000 claims description 5
- 108700020467 WT1 Proteins 0.000 claims description 5
- 101150084041 WT1 gene Proteins 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 230000002611 ovarian Effects 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 235000019833 protease Nutrition 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 102000008178 Cyclin B1 Human genes 0.000 claims description 3
- 108010060385 Cyclin B1 Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 4
- 102000016736 Cyclin Human genes 0.000 claims 2
- 108050006400 Cyclin Proteins 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000013615 primer Substances 0.000 description 130
- 239000013612 plasmid Substances 0.000 description 44
- 230000001177 retroviral effect Effects 0.000 description 36
- 239000000523 sample Substances 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 238000013459 approach Methods 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 230000003321 amplification Effects 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 17
- 239000013600 plasmid vector Substances 0.000 description 17
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 230000002093 peripheral effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000012986 modification Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 101800001494 Protease 2A Proteins 0.000 description 6
- 101800001066 Protein 2A Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 5
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 5
- 108020005067 RNA Splice Sites Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 238000007702 DNA assembly Methods 0.000 description 4
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 4
- 102100029075 Exonuclease 1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000013414 tumor xenograft model Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 229930191564 Monensin Natural products 0.000 description 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229960005358 monensin Drugs 0.000 description 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 101000658374 Homo sapiens T cell receptor alpha variable 12-3 Proteins 0.000 description 2
- 101000658382 Homo sapiens T cell receptor alpha variable 26-2 Proteins 0.000 description 2
- 101000772121 Homo sapiens T cell receptor alpha variable 30 Proteins 0.000 description 2
- 101000794425 Homo sapiens T cell receptor alpha variable 36/delta variable 7 Proteins 0.000 description 2
- 101000795961 Homo sapiens T cell receptor alpha variable 38-1 Proteins 0.000 description 2
- 101000844038 Homo sapiens T cell receptor beta variable 10-2 Proteins 0.000 description 2
- 101000939858 Homo sapiens T cell receptor beta variable 12-4 Proteins 0.000 description 2
- 101000658410 Homo sapiens T cell receptor beta variable 2 Proteins 0.000 description 2
- 101000658429 Homo sapiens T cell receptor beta variable 3-1 Proteins 0.000 description 2
- 101000606215 Homo sapiens T cell receptor beta variable 6-4 Proteins 0.000 description 2
- 101000844025 Homo sapiens T cell receptor beta variable 7-6 Proteins 0.000 description 2
- 101000844022 Homo sapiens T cell receptor beta variable 7-9 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100034846 T cell receptor alpha variable 12-3 Human genes 0.000 description 2
- 102100034842 T cell receptor alpha variable 26-2 Human genes 0.000 description 2
- 102100029314 T cell receptor alpha variable 30 Human genes 0.000 description 2
- 102100030195 T cell receptor alpha variable 36/delta variable 7 Human genes 0.000 description 2
- 102100031724 T cell receptor alpha variable 38-1 Human genes 0.000 description 2
- 102100032167 T cell receptor beta variable 10-2 Human genes 0.000 description 2
- 102100029697 T cell receptor beta variable 12-4 Human genes 0.000 description 2
- 102100034891 T cell receptor beta variable 2 Human genes 0.000 description 2
- 102100034887 T cell receptor beta variable 3-1 Human genes 0.000 description 2
- 102100039750 T cell receptor beta variable 6-4 Human genes 0.000 description 2
- 102100032178 T cell receptor beta variable 7-6 Human genes 0.000 description 2
- 102100032192 T cell receptor beta variable 7-9 Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007860 single-cell PCR Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010033222 HLA-DRB1*04 antigen Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000772137 Homo sapiens T cell receptor alpha variable 1-1 Proteins 0.000 description 1
- 101000772138 Homo sapiens T cell receptor alpha variable 1-2 Proteins 0.000 description 1
- 101000795989 Homo sapiens T cell receptor alpha variable 10 Proteins 0.000 description 1
- 101000795920 Homo sapiens T cell receptor alpha variable 12-1 Proteins 0.000 description 1
- 101000658376 Homo sapiens T cell receptor alpha variable 12-2 Proteins 0.000 description 1
- 101000658380 Homo sapiens T cell receptor alpha variable 13-1 Proteins 0.000 description 1
- 101000658378 Homo sapiens T cell receptor alpha variable 13-2 Proteins 0.000 description 1
- 101000772135 Homo sapiens T cell receptor alpha variable 14/delta variable 4 Proteins 0.000 description 1
- 101000772136 Homo sapiens T cell receptor alpha variable 16 Proteins 0.000 description 1
- 101000772143 Homo sapiens T cell receptor alpha variable 17 Proteins 0.000 description 1
- 101000772144 Homo sapiens T cell receptor alpha variable 18 Proteins 0.000 description 1
- 101000772141 Homo sapiens T cell receptor alpha variable 19 Proteins 0.000 description 1
- 101000772111 Homo sapiens T cell receptor alpha variable 2 Proteins 0.000 description 1
- 101000772109 Homo sapiens T cell receptor alpha variable 20 Proteins 0.000 description 1
- 101000772110 Homo sapiens T cell receptor alpha variable 21 Proteins 0.000 description 1
- 101000772107 Homo sapiens T cell receptor alpha variable 22 Proteins 0.000 description 1
- 101000772108 Homo sapiens T cell receptor alpha variable 23/delta variable 6 Proteins 0.000 description 1
- 101000772105 Homo sapiens T cell receptor alpha variable 24 Proteins 0.000 description 1
- 101000772106 Homo sapiens T cell receptor alpha variable 25 Proteins 0.000 description 1
- 101000658384 Homo sapiens T cell receptor alpha variable 26-1 Proteins 0.000 description 1
- 101000772113 Homo sapiens T cell receptor alpha variable 27 Proteins 0.000 description 1
- 101000772114 Homo sapiens T cell receptor alpha variable 29/delta variable 5 Proteins 0.000 description 1
- 101000794417 Homo sapiens T cell receptor alpha variable 3 Proteins 0.000 description 1
- 101000794423 Homo sapiens T cell receptor alpha variable 34 Proteins 0.000 description 1
- 101000794422 Homo sapiens T cell receptor alpha variable 35 Proteins 0.000 description 1
- 101000794424 Homo sapiens T cell receptor alpha variable 39 Proteins 0.000 description 1
- 101000794420 Homo sapiens T cell receptor alpha variable 4 Proteins 0.000 description 1
- 101000794419 Homo sapiens T cell receptor alpha variable 40 Proteins 0.000 description 1
- 101000794418 Homo sapiens T cell receptor alpha variable 41 Proteins 0.000 description 1
- 101000794371 Homo sapiens T cell receptor alpha variable 5 Proteins 0.000 description 1
- 101000794370 Homo sapiens T cell receptor alpha variable 6 Proteins 0.000 description 1
- 101000794373 Homo sapiens T cell receptor alpha variable 7 Proteins 0.000 description 1
- 101000794372 Homo sapiens T cell receptor alpha variable 8-1 Proteins 0.000 description 1
- 101000794374 Homo sapiens T cell receptor alpha variable 8-3 Proteins 0.000 description 1
- 101000794369 Homo sapiens T cell receptor alpha variable 9-1 Proteins 0.000 description 1
- 101000794368 Homo sapiens T cell receptor alpha variable 9-2 Proteins 0.000 description 1
- 101000844037 Homo sapiens T cell receptor beta variable 10-1 Proteins 0.000 description 1
- 101000844035 Homo sapiens T cell receptor beta variable 10-3 Proteins 0.000 description 1
- 101000844036 Homo sapiens T cell receptor beta variable 11-1 Proteins 0.000 description 1
- 101000939856 Homo sapiens T cell receptor beta variable 11-3 Proteins 0.000 description 1
- 101000939859 Homo sapiens T cell receptor beta variable 12-3 Proteins 0.000 description 1
- 101000939743 Homo sapiens T cell receptor beta variable 12-5 Proteins 0.000 description 1
- 101000658388 Homo sapiens T cell receptor beta variable 13 Proteins 0.000 description 1
- 101000658386 Homo sapiens T cell receptor beta variable 14 Proteins 0.000 description 1
- 101000658391 Homo sapiens T cell receptor beta variable 16 Proteins 0.000 description 1
- 101000658398 Homo sapiens T cell receptor beta variable 19 Proteins 0.000 description 1
- 101000939742 Homo sapiens T cell receptor beta variable 20-1 Proteins 0.000 description 1
- 101000939745 Homo sapiens T cell receptor beta variable 24-1 Proteins 0.000 description 1
- 101000939744 Homo sapiens T cell receptor beta variable 25-1 Proteins 0.000 description 1
- 101000658400 Homo sapiens T cell receptor beta variable 27 Proteins 0.000 description 1
- 101000658406 Homo sapiens T cell receptor beta variable 28 Proteins 0.000 description 1
- 101000658404 Homo sapiens T cell receptor beta variable 29-1 Proteins 0.000 description 1
- 101000658408 Homo sapiens T cell receptor beta variable 30 Proteins 0.000 description 1
- 101000606204 Homo sapiens T cell receptor beta variable 5-1 Proteins 0.000 description 1
- 101000606214 Homo sapiens T cell receptor beta variable 5-6 Proteins 0.000 description 1
- 101000606212 Homo sapiens T cell receptor beta variable 5-8 Proteins 0.000 description 1
- 101000606218 Homo sapiens T cell receptor beta variable 6-1 Proteins 0.000 description 1
- 101000606217 Homo sapiens T cell receptor beta variable 6-2 Proteins 0.000 description 1
- 101000606220 Homo sapiens T cell receptor beta variable 6-5 Proteins 0.000 description 1
- 101000606219 Homo sapiens T cell receptor beta variable 6-6 Proteins 0.000 description 1
- 101000844023 Homo sapiens T cell receptor beta variable 7-7 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108700002010 MHC class II transactivator Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100029309 T cell receptor alpha variable 1-1 Human genes 0.000 description 1
- 102100029308 T cell receptor alpha variable 1-2 Human genes 0.000 description 1
- 102100031333 T cell receptor alpha variable 10 Human genes 0.000 description 1
- 102100031722 T cell receptor alpha variable 12-1 Human genes 0.000 description 1
- 102100034847 T cell receptor alpha variable 12-2 Human genes 0.000 description 1
- 102100034849 T cell receptor alpha variable 13-1 Human genes 0.000 description 1
- 102100034848 T cell receptor alpha variable 13-2 Human genes 0.000 description 1
- 102100029304 T cell receptor alpha variable 14/delta variable 4 Human genes 0.000 description 1
- 102100029302 T cell receptor alpha variable 16 Human genes 0.000 description 1
- 102100029306 T cell receptor alpha variable 17 Human genes 0.000 description 1
- 102100029300 T cell receptor alpha variable 18 Human genes 0.000 description 1
- 102100029307 T cell receptor alpha variable 19 Human genes 0.000 description 1
- 102100029486 T cell receptor alpha variable 2 Human genes 0.000 description 1
- 102100029488 T cell receptor alpha variable 20 Human genes 0.000 description 1
- 102100029487 T cell receptor alpha variable 21 Human genes 0.000 description 1
- 102100029482 T cell receptor alpha variable 22 Human genes 0.000 description 1
- 102100029489 T cell receptor alpha variable 23/delta variable 6 Human genes 0.000 description 1
- 102100029484 T cell receptor alpha variable 24 Human genes 0.000 description 1
- 102100029483 T cell receptor alpha variable 25 Human genes 0.000 description 1
- 102100034843 T cell receptor alpha variable 26-1 Human genes 0.000 description 1
- 102100029313 T cell receptor alpha variable 27 Human genes 0.000 description 1
- 102100029312 T cell receptor alpha variable 29/delta variable 5 Human genes 0.000 description 1
- 102100030199 T cell receptor alpha variable 3 Human genes 0.000 description 1
- 102100030190 T cell receptor alpha variable 34 Human genes 0.000 description 1
- 102100030191 T cell receptor alpha variable 35 Human genes 0.000 description 1
- 102100031342 T cell receptor alpha variable 38-2/delta variable 8 Human genes 0.000 description 1
- 101710153604 T cell receptor alpha variable 38-2/delta variable 8 Proteins 0.000 description 1
- 102100030189 T cell receptor alpha variable 39 Human genes 0.000 description 1
- 102100030196 T cell receptor alpha variable 4 Human genes 0.000 description 1
- 102100030197 T cell receptor alpha variable 40 Human genes 0.000 description 1
- 102100030198 T cell receptor alpha variable 41 Human genes 0.000 description 1
- 102100030178 T cell receptor alpha variable 5 Human genes 0.000 description 1
- 102100030179 T cell receptor alpha variable 6 Human genes 0.000 description 1
- 102100030182 T cell receptor alpha variable 7 Human genes 0.000 description 1
- 102100030183 T cell receptor alpha variable 8-1 Human genes 0.000 description 1
- 102100030181 T cell receptor alpha variable 8-3 Human genes 0.000 description 1
- 102100030188 T cell receptor alpha variable 9-1 Human genes 0.000 description 1
- 102100030184 T cell receptor alpha variable 9-2 Human genes 0.000 description 1
- 102100032168 T cell receptor beta variable 10-1 Human genes 0.000 description 1
- 102100032172 T cell receptor beta variable 10-3 Human genes 0.000 description 1
- 102100032171 T cell receptor beta variable 11-1 Human genes 0.000 description 1
- 102100029711 T cell receptor beta variable 11-3 Human genes 0.000 description 1
- 102100029696 T cell receptor beta variable 12-3 Human genes 0.000 description 1
- 102100029658 T cell receptor beta variable 12-5 Human genes 0.000 description 1
- 102100034886 T cell receptor beta variable 13 Human genes 0.000 description 1
- 102100034885 T cell receptor beta variable 14 Human genes 0.000 description 1
- 102100034881 T cell receptor beta variable 16 Human genes 0.000 description 1
- 102100034884 T cell receptor beta variable 19 Human genes 0.000 description 1
- 102100029659 T cell receptor beta variable 20-1 Human genes 0.000 description 1
- 102100029656 T cell receptor beta variable 24-1 Human genes 0.000 description 1
- 102100029657 T cell receptor beta variable 25-1 Human genes 0.000 description 1
- 102100034877 T cell receptor beta variable 27 Human genes 0.000 description 1
- 102100034880 T cell receptor beta variable 28 Human genes 0.000 description 1
- 102100034879 T cell receptor beta variable 29-1 Human genes 0.000 description 1
- 102100034890 T cell receptor beta variable 30 Human genes 0.000 description 1
- 102100039739 T cell receptor beta variable 5-1 Human genes 0.000 description 1
- 102100039749 T cell receptor beta variable 5-6 Human genes 0.000 description 1
- 102100039751 T cell receptor beta variable 5-8 Human genes 0.000 description 1
- 102100039787 T cell receptor beta variable 6-1 Human genes 0.000 description 1
- 102100039748 T cell receptor beta variable 6-2 Human genes 0.000 description 1
- 102100039786 T cell receptor beta variable 6-5 Human genes 0.000 description 1
- 102100039785 T cell receptor beta variable 6-6 Human genes 0.000 description 1
- 102100032184 T cell receptor beta variable 7-7 Human genes 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present disclosure relates generally to compositions and methods for rapidly cloning and characterizing T cell receptors.
- Tumor antigen-specific T cells recognize cancer targets via heterodimeric T-cell receptors (TCR) that recognize tumor antigen-derived peptides loaded on major histocompatibility complex (MHC) molecules on cancer cells.
- TCR heterodimeric T-cell receptors
- MHC major histocompatibility complex
- CDR3 complement-determining region 3
- TCR gene-engineered T cells have comparable anti-tumor effects as the parental T-cell clones against cancer targets.
- Clinical trials testing TCR gene-engineered T cells have demonstrated feasibility, safety and therapeutic effects in multiple tumor types.
- only a limited number of therapeutic anti-tumor TCR genes have been developed, which limits the broad application of this powerful therapeutic strategy to cancer patients.
- tumor antigen-specific TCR ⁇ and ⁇ chain genes are obtained from well characterized tumor antigen-specific T-cell clones expanded in vitro.
- establishing tumor antigen-specific T cell clones targeting a broad array of tumor antigens and MHC restriction elements is laborious and technically challenging in a high throughput manner.
- single-cell approaches such as single-cell PCR ( G. C. Wang, P. et al. Sci. Transl. Med. 4, 128ra142 (2012 ); E. Kobayashi, et al. Nat. Med. 19, 1542-1546 (2013 ); S. Seitz, et al. Proc. Natl. Acad. Sci. USA 103, 12057-12062 (2006 ); G.
- next generation sequencing has been utilized to identify paired TCR ⁇ and ⁇ chain sequences from tumor specimens ( C. Linnemann, et al. Nat. Med. 19, 1534-1541 (2013 ); A. Gros, et al. Nat. Med. 22, 433-438 (2016 ); A. Pasetto, Aet al. Cancer Immunol. Res. 4, 734-743 (2016 ); B. Howie, et al. Sci. Transl. Med. 7, 301ra131 (2015 )).
- NGS next generation sequencing
- TCR-expressing cassettes were constructed and cloned in a retroviral plasmid vector within 24-hours by unbiased PCR amplification of TCR ⁇ and ⁇ chain variable regions assembled with TCR constant regions. The method was successfully validated by constructing TCR-expressing vectors from tumor antigen-specific T-cell clones and functional assessment of TCR gene-transduced T cells.
- This method was applied to frozen ovarian tumor specimens that were infiltrated by tumor antigen-specific T cells.
- a tumor-derived TCR library was expressed on peripheral T cells from healthy volunteers for the screening of tumor antigen-specific TCR pairs by using a MHC/peptide tetramer reagent. A single round of screening identified functional tumor antigen-specific TCR pairs.
- Peripheral T cells that were engineered with library-derived TCR gene showed potent therapeutic anti-tumor effect in a tumor xenograft model.
- the presently provided method can therefore efficiently and rapidly provide tumor-specific TCR-expressing viral vectors for the manufacture of therapeutic anti-tumor T-cell products in a personalized manner.
- compositions and methods for cloning a plurality of TCR ⁇ and ⁇ chain variable sequences from T-cell TCRs from any biological sample that contains T cells are disclosed.
- the disclosure is pertinent to cloning TCR ⁇ and ⁇ chain variable sequences from oligoclonal populations of T cells.
- the oligoclonal populations of T cells may comprise T cells that can recognize an antigen expressed by cancer cells, wherein the antigen is associated with a malignant phenotype.
- the disclosure comprises: obtaining RNA from T cells, such as from an oligoclonal population of T cells, wherein the RNA comprises mRNA encoding TCR ⁇ and ⁇ chain variable sequences, and generating first single strand cDNA from the mRNA, wherein the first single strand cDNA includes single stranded cDNA encoding the TCR ⁇ chains and single stranded cDNA encoding the TCR ⁇ chains, wherein the single stranded cDNAs are generated using reverse transcription and oligo-dT primers, to obtain a sample of first strand cDNA amplified from the mRNA.
- the sample comprising first strand cDNA amplified from the mRNA encoding the TCR ⁇ and ⁇ chain variable sequences is divided such that there are at least two samples containing the first strand cDNAs.
- the sample of first strand cDNA amplified from the mRNA from may be divided into first and second samples (which may simply comprise taking an aliquot from the first strand cDNA synthesis reaction and placing it into a separate container), and PCR reactions on the first and second samples are performed to obtain double stranded cDNAs.
- a second-strand cDNA synthesis may be performed to obtain double stranded cDNAs encoding the TCR ⁇ chains.
- HTTCR#C-1 through HTTCR#C-45 in Table 1 This is performed using all or a subset of the primers termed HTTCR#C-1 through HTTCR#C-45 in Table 1 (i.e., using all 45 primers, or a subset of these primers).
- a second-strand cDNA synthesis is performed to obtain double stranded cDNAs encoding the TCR ⁇ chains using all or a subset of the primers HTTCR#F-1 through HTTCR#F-49 in Table 1 (i.e., using all 49 primers, or a subset of these primers).
- the first and second samples are exposed to an exonuclease for a period of time sufficient to degrade primers that were not incorporated into the amplicons, and to degrade single stranded cDNA if present.
- the exonuclease is then inactivated by, for example, using a heat treatment.
- the method involves in the first sample performing a PCR amplification of the amplicons encoding the TCR ⁇ chains using tag-specific primer HTTCR#A - ACTTAAGCTTGGTACCGAGCTCGGATCTGCGGCCGCCACCATG (SEQ ID NO:1) and primer HTTCR#B - CTCAAACACAGCGACCTCGGGTGGGAACAC (SEQ ID NO:2) to obtain amplicons encoding the TCR ⁇ chains, wherein the amplicons encoding the TCR ⁇ chains may further comprise one or a combination of a restriction endonuclease recognition site, a Kozak sequence and a translation initiating ATG sequence.
- the method includes performing in the second sample a PCR amplification of the amplicons encoding the TCR ⁇ chains using tag-specific primer HTTCR#D GGAGACGTGGAAGAAAACCCCGGTCCCATG (SEQ ID NO:48) and HT-TCR#E AGGCAGACAGACTTGTCACTGGATTTAGAG (SEQ ID NO:49) to obtain amplicons encoding the TCR ⁇ chains, wherein the amplicons may further comprise a P2A sequence and an initiating ATG sequence.
- the method then involves assembling the amplicons encoding the TCR ⁇ chains and the TCR ⁇ chains into DNA vectors to provide a plurality of DNA vectors each comprising DNA segments encoding only one of the TCR ⁇ chains and only one of the TCR ⁇ chains.
- the vectors can encode distinct TCR ⁇ and TCR ⁇ chain pairs that were not expressed together by any of the T cells in the sample used as the starting material for the cloning process.
- TCR ⁇ and TCR ⁇ chain may be connected by a DNA linker fragment such as 2A-translational skipping site fragment.
- the assembly of the chains can be performed by, for example mixing the amplicons encoding the TCR ⁇ and TCR ⁇ chains with one or two DNA fragments, such as with a common or invariable TCR C ⁇ -2A fragment, or TCR C ⁇ -2A fragment and TCR C ⁇ fragment.
- Non-limiting examples of this aspect of the disclosure are illustrated in Figure 1 step 5 and Figure 18 .
- Other techniques can also be employed for the vector assembly, including but not necessarily limited to ligation-independent cloning, Gibson assembly cloning, or any similar techniques to assemble the vector that will be recognized by those skilled in the art, given the benefit of this disclosure.
- the fragments may be assembled as a single fragment comprising the segments encoding the TCR V ⁇ , C ⁇ , 2A, V ⁇ sequence by overlapping PCR using for example the HTTCR#A ⁇ chain-tag-specific forward primer and the HTTCR#E reverse primer.
- a non-limiting example of this approach is depicted in Figure 16A .
- a plurality of DNA vectors may be provided, and each vector in the plurality may encode only a single TCR ⁇ chain and a single TCR ⁇ chain from the TCRs from T cells.
- the disclosure may use as a starting material a population of oligoclonal T cells, which may comprise T cells that have infiltrated a tumor.
- the type of tumor is not particularly limited, and in embodiments includes bladder, brain, breast, ovarian, lung, renal, colon, stomach, pancreas, prostate or liver cancer, myeloma, a sarcoma, a tumor formed from leukemia, lymphoma, or a melanoma.
- the sample used as a starting material may comprise cancer cells that express immunogenic tumor antigens, non-limiting examples of which comprise NY-ESO-1, WT1, MUC1, LMP2, HPV E6 and E7, EGFRvIII, HER2/neu, MAGE-A3, p53, NY-ESO-1, PSMA, GD2, CEA, MalanA/MART1, mutated Ras, gp100, Proteinase 3, bcr-abl, Tyrosinase, Survivin, PSA, hTERT, MAGE-A1, MAGE-A4, MAGE-C1, MAGE-C2, PLAC1, Sp17, TRP-2, Cyclin B1, Mesothelin, Folate Receptor alpha, and patient specific neoantigens.
- DNA vectors made by a process of this disclosure may be capable of expressing the TCR ⁇ and the TCR ⁇ chains in lymphocytes such that the lymphocytes exhibit antigen specificity against an antigen expressed by a cancer cell.
- the disclosure includes introducing into lymphocytes at least one of the DNA vectors and allowing expression of the TCR ⁇ chain and the TCR ⁇ chain encoded by the at least one vector such that the lymphocytes express a functional TCR comprising the TCR ⁇ chain and the TCR ⁇ chain.
- the disclosure includes determining whether or not the lymphocytes exhibit antigen specificity against an antigen expressed by cancer cells.
- the disclosure also includes cell of any type, including lymphocytes that comprise at least one DNA vector made according to any method of this disclosure. Such lymphocytes can recognize any cancer cell type and any antigen that is the same as the cancer cell types and antigens that T cells in the starting material sample can recognize. Such lymphocytes may have also exhibit improved antigen recognizing properties.
- Kits contain combinations of primers described herein, as well as reagents for performing the methods of this disclosure, such as a destination vector(s) comprising a suitable restriction endonuclease recognition sequences, and a segment encoding a cysteine-modified C ⁇ fragment.
- the reagents may also include one or more buffers for performing first strand cDNA synthesis, and/or second strand cDNA synthesis, and for example, a reverse transcriptase and/or a DNA polymerase.
- a method for cloning a plurality of TCR ⁇ and ⁇ chain variable sequences from T-cell receptors (TCRs) from an oligoclonal population of T cells as is set forth in Claim 1 of the accompanying claims.
- a lymphocyte comprising at least one DNA vector made according to the method of the first aspect of the invention, as is set forth in Claim 9 of the accompanying claims.
- a kit as is set forth in Claim 12 of the accompanying claims.
- the present disclosure relates generally to adoptive transfer of autologous tumor antigen-specific T cells, which is an effective therapeutic treatment for cancer patients.
- Gene-engineering of patients' peripheral T cells with tumor antigen-specific TCR or chimeric antigen receptor (CAR) gene is a practical approach to overcome challenges in obtaining sufficient numbers of tumor antigen-specific T cells from patients' specimens.
- CAR chimeric antigen receptor
- TCR rather than CAR genes may be more suitable for manufacture of therapeutic T-cell products.
- a large panel of TCR genes specific for different tumor antigens and HLA restriction elements are required for treatment of wide population of patients with different tumor types.
- the present disclosure relates to the discovery of tumor antigen-specific TCR ⁇ and ⁇ chain pairs, and provides a rapid method to construct randomly paired TCR-expression library from tumor tissues that are infiltrated by tumor antigen-specific T cells.
- the current method only requires snap frozen tumor specimens, which can be prepared at most clinical sites, although it is applicable to freshly obtained samples.
- variable regions of TCR ⁇ and ⁇ chains were amplified by common primers, but not TCR V ⁇ or V ⁇ -specific multiplexed primers, in order to minimize PCR bias. These variable fragments were assembled as expression cassettes using a highly efficient cloning platform.
- a tumor-infiltrating T cell-derived TCR library can be prepared as retroviral expression plasmids within 24-hours, as outlined in Figure 20 .
- the TCRs obtained by this unique approach were functional as evidenced by in vitro tumor recognition.
- we demonstrated the therapeutic potential of the library-derived TCRs by adoptively transferring the T cells in a tumor xenograft model.
- tumor-derived TCR-expression library a tumor-derived library
- tumor-derived library did not contain significant fraction of tumor-reactive TCRs, although the original tumor specimen contained high frequency tetramer-reactive CD8+ T cells. It is possible that the specimen that was used for single cell suspension for T-cell staining and that for RNA extraction contained different fractions of tetramer-reactive T cells.
- tetramer-reactive T cells could be composed of oligoclonal populations, for which the probability to form functional TCR pairs in the library exponentially decreases.
- a library (3 ⁇ 10 5 ) was used to perform screening. This library size is considered to be sufficient to obtain correct TCR pairs from a T-cell clone of more than 1% frequency among total T cells, and given the benefit of this disclosure, the library size could be easily expanded by the use of electro-competent cells to identify specific TCR pairs from less frequent T-cell clones.
- TCR gene-engineered T cell product is a serious problem in identification of high affinity non-natural TCRs as found in an affinity enhanced TCR or a murine TCR.
- candidates for therapeutic TCR genes identified by the current method can be more extensively tested for cross-reactivity against a panel of normal tissues and genes that contain homologous sequences of the TCR epitope.
- the present disclosure establishes a new and fast method for discovery and identification of relevant TCRs that can be directly utilized in a viral vector construct form for downstream translational validation towards an effective therapeutic adoptive cell therapy for cancer.
- a "recombinant TCR” means a TCR that is encoded by and capable of being expressed from a polynucleotide that is introduced into a cell, meaning prior to the introduction of the polynucleotide the TCR was not encoded by a chromosomal sequence in the cell.
- compositions and methods provided by this disclosure include oligonucleotide primers, and thus can include a primer component.
- the primer component of this disclosure comprises or consists of any combination of the primer sequences, wherein the primer sequences are selected from the sequences that are presented in the Table of this disclosure.
- the disclosure includes all cloning steps, and all cloning intermediates, including but not necessarily to primers annealed to RNA and/or DNA, fully and partially double stranded amplicons, restriction digests and fragments thereof, including fragments that are blunt ended or have 5' or 3' single stranded overhangs, linearized plasmids, overlapping primers, and the like. Certain steps of the methods described herein can be performed sequentially, or concurrently, and can be performed in single or separate reactions, as will be apparent from the description of particular examples and the figures.
- the disclosure relates to cloning, expression, and functional characterization of TCRs that are expected to be useful in development of, and use in, therapeutic approaches applicable to a wide variety of conditions.
- the disclosure pertains to the identification and cloning of TCRs that are useful for generating T-cells that are programmed to have specificity for a desired antigen, and wherein the TCRs are compatible with the HLA type of any given individual.
- the method comprises subjecting a population of mammalian cells comprising or consisting of T cells to a polynucleotide extraction step, amplifying TCR coding regions from the extracted polynucleotides, modifying the amplified polynucleotides such that they are suitable for incorporation into a recombinant vector, and incorporating the polynucleotide sequences encoding at least TCR ⁇ and ⁇ chain coding sequences into a recombinant expression vector.
- the incorporated sequences can accordingly comprise a combination of V ⁇ , D ⁇ , j ⁇ , sequences, constant regions (i.e., a ⁇ chain constant region and a ⁇ chain constant region), and a V ⁇ and J ⁇ region, as well as other sequences.
- the expression vector(s) is accordingly configured to express recombinant TCR polypeptides that were amplified from population of cells obtained from one or more individuals.
- Figure 11 A non-limiting illustration of a PCR amplification template of this disclosure is provided by Figure 11 , which depicts a TCR ⁇ and ⁇ chain mRNA.
- the type of cells that provide the starting material for the TCR cloning process of this disclosure are not particularly limited, provided that at least some cells that are subjected to the cloning procedure include cells that encode TCRs.
- the disclosure includes rapid TCR cloning approaches that are suitable for use with biological samples comprising T cells obtained from any mammal, including humans and non-human mammals, and is therefore expected to be suitable for identifying native TCR sequences, and generating recombinant TCRs that can be used in human and veterinary therapeutic implementations.
- the biological sample can be any biological sample that would be expected to contain T cells, including but not necessarily limited to liquid biological samples, such as blood lymph or bone marrow, and solid biological samples of, for example, lymph nodes, spleen, tumors, or thymus.
- liquid biological samples such as blood lymph or bone marrow
- solid biological samples of, for example, lymph nodes, spleen, tumors, or thymus.
- the method may be performed on a population of cells that are obtained from an individual, wherein the population is expected to include T cells that comprise and/or encode a TCR ⁇ and a TCR ⁇ chain.
- the population may also include T cells that include ⁇ T cells, but the ⁇ TCR will not be detected using the methods of this disclosure.
- the cells that are used for the TCR cloning procedure of this disclosure can comprise peripheral blood mononuclear cells (PBMCs) and thus may comprise T cells, B cells, natural killer cells, natural killer T cells, and monocytes.
- PBMCs peripheral blood mononuclear cells
- the T-cells may be a mixture of T cell types or single cells, which include but are not necessarily limited to CD4+ T cells and CD8+ T cells.
- the T cells may be T helper cells (T H cells), Cytotoxic T cells (T C cells, or CTLs), suppressor T cells, such as CD4 + T reg cells, or naive, stem cell memory, effector, memory, intraepithelial, or tissue-resident memory T cells.
- T H cells T helper cells
- T C cells Cytotoxic T cells
- suppressor T cells such as CD4 + T reg cells, or naive, stem cell memory, effector, memory, intraepithelial, or tissue-resident memory T cells.
- the cells may be a partially or fully purified population of cells, or T cell clones that can be obtained using established techniques, such as by cell sorting or by cell culture.
- TCRs which comprise a TCR ⁇ and a TCR ⁇ chain, wherein subsequent to expression the two chains are present in a physical association with one another (e.g., in a complex) and are non-covalently joined to one another, or wherein the two chains are distinct polypeptides but are covalently joined to one another, such as by a disulfide or other covalent linkage that is not a peptide bond, or wherein the two chains are connected by a polypeptide linker, i.e., a single chain TCR.
- the fusion protein may comprise a TCR ⁇ chain amino acid sequence and a TCR ⁇ chain amino acid sequence that have been translated from the same open reading frame (ORF), or distinct ORFs, or an ORF that contain a signal that results in non-continuous translation.
- the ORF may comprise a 2A-mediated translation skipping site positioned between the TCR ⁇ and TCR ⁇ chain. Constructs for making 2A containing proteins (also referred to as 2A Peptide-Linked multicistronic vectors) are known in the art.
- 2A peptide sequences when included between coding regions, allow for stoichiometric production of discrete protein products within a single vector through a novel cleavage event that occurs in the 2A peptide sequence.
- 2A peptide sequences are generally short sequence comprising 18-22 amino acids and can comprise distinct amino-terminal sequences.
- a fusion protein may include a P2A amino acid sequence.
- a fusion protein can comprise a linker sequence between the TCR ⁇ and TCR ⁇ chains.
- the linker sequence can comprise from 3-30 amino acids, inclusive.
- the linker sequences may comprise a GSG (Gly-Ser-Gly) linker or an SGSG (Ser-Gly-Ser-Gly) (SEQ ID NO:118) linker.
- the TCR ⁇ and TCR ⁇ chains may be connected to one another by an amino acid sequence that comprises a furin protease recognition site, such as an RAKR (Arg-Ala-Lys-Arg) (SEQ ID NO:119) site.
- RAKR Arg-Ala-Lys-Arg
- the expression construct that is made using the rapid cloning methods of this disclosure may encode a TCR and may also include additional or alternative polynucleotides.
- the additional polynucleotides can be such that they enable cloning of TCR into expression plasmids, for example restriction enzyme sites or overlapping sequences with plasmids.
- the additional polynucleotides can be such that they enhance expression of TCR, for example the Kozak consensus sequence.
- the additional polynucleotides can be such that they enhance formation of TCR heterodimer complex, for example cysteine modifications in the TCR constant regions.
- the additional polynucleotide can be such that they enable identification of TCR expressing cells, such as by adding a short tag sequence detected by antibodies such as c-Myc, V5, or poly-histidine or by encoding a detectable marker, such as a fluorescent or luminescent protein.
- the additional polynucleotides can be such that they encode an element that allows for selective elimination of TCR expressing cells, such as a thymidine kinase gene.
- a method is disclosed that is applicable to rapid cloning of TCRs from single cells/T cell clones, and is also applicable to rapid cloning of TCRs from oligoclonal T cells.
- An "oligoclonal population of T cells" as used herein means a plurality of distinct T cells wherein each T cell in the plurality has a distinct TCR, and wherein the plurality of distinct T cells has in common antigenic agent that comprises at least one antigen that can be recognized by at least some T cells in the population.
- Antigenic agents as such may comprise pathogens, including but not limited to pathogenic microorganisms and viruses, and mammalian proteins and other antigenic determinants.
- cancer cells may be antigenic agents that express one or more cancer antigens that can be recognized either directly by at least some of the T cells in the oligoclonal population, or can be recognized when presented to the T cells by other cells such as dendritic cells in the context of, for example, a major histocompatibility complex (MHC), i.e., in the context of human leukocyte antigen (HLA).
- MHC major histocompatibility complex
- HLA human leukocyte antigen
- An oligoclonal population of T Cells can be obtained from a tissue sample.
- the tissue sample may comprise a sample of a tumor, wherein the T cells have infiltrated the tumor, the sample thus comprising an oligoclonal population tumor-infiltrating T-lymphocytes.
- the disclosure may comprise obtaining total RNA from a sample. "Obtaining" RNA can mean taking a sample, or receiving any sample that contains RNA. Total RNA or mRNA can if desired be separated from any sample using any of a variety of known approaches. Separation of mRNA may not be necessary because total RNA, or a cell lysate containing RNA, can be used as starting material for amplification of mRNA encoding TCR RNAs as further described herein.
- the sample can comprise any portion of the tumor, including but not limited to a single or pooled tumor biopsies, whole tumors, samples of primary tumors, metastasized tumors, metastatic foci, and the like.
- the disclosure may comprise determining TCRs from tumor infiltrating T cells, wherein the tumor is any solid tumor, or a solid tumor formed from, for example, a liquid tumor.
- the cancer comprise a type of cancer selected from bladder, brain, breast, ovarian, lung, renal, colon, stomach, pancreas, prostate or liver cancer, myeloma, a sarcoma, leukemia, lymphoma, or melanoma.
- the cancer may comprise cancer cells that express one or more immunogenic tumor antigens.
- the one or more cancer antigens can comprise any of NY-ESO-1, WT1, MUC1, LMP2, HPV E6 and E7, EGFRvIII, HER2/neu, MAGE-A3, p53, NY-ESO-1, PSMA, GD2, CEA, MalanA/MART1, mutated Ras, gp100, Proteinase 3, bcr-abl, Tyrosinase, Survivin, PSA, hTERT, MAGE-A1, MAGE-A4, MAGE-C1, MAGE-C2, PLAC1, Sp17, TRP-2, Cyclin B1, Mesothelin, or Folate Receptor alpha.
- the cancer can express patient specific neoantigens, i.e., a newly formed antigen that has not been previously recognized by the immune system.
- Tumor-infiltrating T cells can be isolated for example by using antibodies for T cells, but isolation of tumor-infiltrating T cells is not compulsory to perform methods of this disclosure.
- the cancer may be of any stage. There is no particular limit to the individual from whom the sample is obtained, and thus the individual can be a human, a non-human mammal, and can be any age, gender, or ethnicity. Further, the individual may be of any HLA type.
- the sample can be any size, provided that the sample contains at least one T cell. For example, a single T cell from tumor tissue, or any size sample of tumor tissue can be used in this disclosure. A tumor biopsy can be used.
- the diversity of TCRs as determined by distinct combinations of specific ⁇ chain and ⁇ chain variable sequences in an oligoclonal population of T cells of this disclosure can range from, for example, several distinct TCRs, to several hundred-thousand distinct TCRs.
- the disclosure thus comprises determining at least one distinct TCR, and up to one hundred thousand TCRs, or more, from an oligoclonal T cell population.
- the disclosure may comprise obtaining a sample of a tumor from an individual, separating T cells from the tumor or using the whole tumor tissue, isolating total or mRNA containing TCR- ⁇ and ⁇ chain coding mRNA from the T cells, producing single stranded and/or double stranded cDNA from the mRNA, cloning the cDNA into a vector, and determining the sequence of the DNA encoding the TCR- ⁇ and ⁇ chains, and/or determining the amino acid sequence of the TCR- ⁇ and ⁇ chains.
- the disclosure includes optionally expressing the TCR- ⁇ and ⁇ chains recombinantly for, for example, adoptive immunotherapy for an individual who has a type of cancer that expresses an antigen that can be recognized by lymphocytes that express the recombinant TCR.
- Libraries comprising TCR-encoding polynucleotides obtained from oligoclonal T cell populations are included.
- the disclosure also includes cells, such as a plurality of distinct cells and/or cell types, which comprise the recombinant polynucleotides.
- the cells can be isolated cells, cells grown and/or expanded and/or maintained in culture, and can be prokaryotic or eukaryotic cells or recombinant viruses. Prokaryotic and eukaryotic cell cultures and recombinant viruses can be used, for example, to propagate or amplify the TCR expression vectors.
- Modified T cells that are engineered to express a TCR identified by methods of this disclosure may be tested for specificity for any particular antigen.
- the disclosure provides for screening, including but not necessarily limited to high-throughput approaches, a plurality of TCRs that are incorporated into expression vectors as described herein.
- Screening can be based on the capability to bind to the MHC/peptide complex, such as by staining with fluorescent MHC/peptide multimers. Screening can be based on the capability to produce molecules upon binding to the MHC/peptide complex, such as cytokines. TCRs can be expressed on reporter cell lines that are engineered to express fluorescent or luminescent molecules or molecules that are detected by antibodies upon binding to MHC/peptide complex.
- Expression vectors for use with this disclosure can be any suitable expression vector.
- the expression vector may comprise a modified viral polynucleotide, such as from a retroviral or such as a lentiviral vector.
- the disclosure comprises the steps as outlined in Figures 1 and Figure 13 namely: 1) obtaining mRNA encoding TCR ⁇ and ⁇ chain variable sequences from a population of T cells, such as a population of oligoclonal T cells from, for example, a tumor sample, and generating single stranded cDNA from the mRNA, including single stranded cDNA encoding the TCR ⁇ chains and single stranded cDNA encoding the TCR ⁇ chains, wherein the single stranded cDNAs are generated using any suitable reverse transcriptase and, for example oligo-dT primers or any other suitable primers;
- the disclosure may include using subsets of the primers in Table 1, and in certain implementations includes using subsets of the #C primers, and using subsets of the #F primers.
- a subset of primers can be selected where a specific V ⁇ subtype(s) is used by the tumor antigen-specific T cells. This can be ascertained from, for example, flow cytometry using V ⁇ or V ⁇ subtype-specific antibodies.
- the disclosure may include subpools of primer mixes, for example, instead of mixing all the #C primers and mixing all the #F primers, 5 subpools of about 10 primers/each subpool can be used, i.e., primer subpools A,B,C,D,E for alpha and F,G,H,I,J for beta.
- a common TCR C ⁇ -2A fragment can be used, and can be prepared by for example, PCR using primers HTTCR#G and HTTCR#H from the template plasmid containing C ⁇ -2A fragment.
- Preparation of TCR C ⁇ -2A fusion fragments by PCR amplification from a template plasmid is shown in Figure 16C . If the amplicons are mixed with two DNA fragments they can be mixed with, for example, the C ⁇ -2A fragment and a Ca fragment as shown in Figure 18 and assembled into a contiguous fragment by, for example, ligation-independent cloning.
- the foregoing steps can all be performed in the case where the T cells are polyclonal or oligoclonal as well as for single T cells and T cell clones, but it is preferable for single T cells and T cell clones (i.e., there is only one TCR species per reaction where PCR bias by multiplexed V ⁇ or V ⁇ -specific primers is not a concern) to omit step 3 (subjecting the reactions the nuclease treatment), and to combine steps 2 and 4, i.e., there is no need for a nuclease or heat inactivation of unused primers, and the second-strand cDNA synthesis to produce the cDNA amplicons encoding the TCR ⁇ chains the cDNA amplicons encoding the TCR ⁇ chains (in separate reactions) can be performed concurrently.
- steps 2 and 4 can be combined for ⁇ chain amplification by using all of the HTTCR#A ⁇ chain-tag-specific forward primers, the HTTCR#B C ⁇ -specific reverse primer, and all of the HTTCR#C primers.
- all of the HTTCR#D primers can be used with the HTTRC#E C ⁇ -specific reverse primer, and all of the HTTCR#F primers. All primer concentrations depicted the figures are included in this disclosure. Aspects of the current approach were tested in multiple configurations and conditions, using distinct primer combinations, polymerases and purification methods, yielding more than 10 failed attempts to achieve suitable results.
- the disclosure may include use of two different destination vectors, one of which is suitable for ligation-independent cloning and the other is suitable for restriction enzyme-ligase cloning.
- the C ⁇ region which is included in these vectors are modified to introduce restriction enzyme sites, but the sequence after cloning encodes the natural C ⁇ sequence, and thus the cloning approach may be scar-free with respect to the C ⁇ sequence.
- an expression vector can contain a C ⁇ fragment.
- artificial restriction enzyme site is introduced in the C ⁇ region.
- GGGCCC sequence which is recognized by PspOMI (or Bsp120I) enzyme was introduced.
- a forward (PspOMI-C ⁇ -F) and reverse primers (PspOMI-C ⁇ -R) that contain GGGCCC sequence was designed.
- Two PCR reactions is performed using unmodified TCR-expression cassette as a template using HTTCR#A and PspOMI-C ⁇ -R, and HTTCR#J and PspOMI-C ⁇ -F. Resulting amplicons are connected by overlapping PCR using HTTCR#A and HTTCR#J and cloned into an expression vector.
- Additional Primer Sequence include:
- Ligation of TCR V ⁇ PCR fragment into PspOMI-treated expression vector is performed using ligation-independent cloning methods such as Gibson Assembly and NEBuilder HiFi DNA Assembly, both of which are available as a kit from New England Biolabs. These methods utilize 5' Exonuclease to create complementary ends between two fragments. 5' Exonuclease destroy 5' overhang produced by PspOMI. As a result, ligation product becomes the natural C ⁇ sequence. Similar ligation-independent cloning methods may use 3' Exonuclease such as InFusion cloning which is available from Clontech. In this case, Apal, which recognizes the same GGGCCC sequence but produces 3' over-hang, may be used.
- ligation-independent cloning methods such as Gibson Assembly and NEBuilder HiFi DNA Assembly, both of which are available as a kit from New England Biolabs. These methods utilize 5' Exonuclease to create complementary ends between two fragment
- the disclosure provides a vector and related method to clone assembled fragments using restriction enzymes.
- an assembled TCR V ⁇ -C ⁇ -V ⁇ fragment can be cloned into an expression plasmid vector containing TCR C ⁇ fragment by using DNA ligase followed by restriction enzymes.
- artificial restriction enzyme site is introduced in the C ⁇ region.
- TCGCGA sequence which is recognized by Nrul (or Rrul) enzyme was introduced.
- PCR reactions Two PCR reactions is performed using unmodified TCR-expression cassette as a template using HTTCR#A and NruI-C ⁇ -R, and HTTCR#J and NruI-C ⁇ -F. Resulting amplicons are connected by overlapping PCR using HTTCR#A and HTTCR#J and cloned into an expression vector. Additional primer sequences include:
- HTTCR#E was replaced by HTTCR#E-SwaI primer which contains ATTTAAAT sequence which is recognized by Swal (or Smil).
- NNN represents any 3 nucleotide sequence to increase efficiency of restriction enzyme reaction.
- An additional primer sequence includes: HTTCR#E-SwaI: NNNATTTAAATCGGTGAATAGGCAGACAGACTTGT (SEQ ID NO: 104).
- An assembled TCR V ⁇ -C ⁇ -2A-V ⁇ fragment for example created by 3 fragments overlapping PCR as shown in Figure 16 , may be treated with NotI and Swal restriction enzymes.
- NotI-recognizing sequence GCGGCCGC
- Swal-recognizing sequence ATTTAAAT
- the probability to create these 8 nucleotides sequence by random nucleotide insertion and deletion during TCR recombination process is extremely low.
- Nrul-modified plasmid vector is treated by NotI and Nrul restriction enzymes.
- Assembled TCR fragment and plasmid vector are ligated by using DNA ligase. Ligation of Swal-treated TCR fragment and Nrul-treated C ⁇ fragment in the plasmid produces nucleotide sequence encoding natural C ⁇ amino acid sequence.
- methods of this disclosure comprise amplifying TCR coding regions from polynucleotides extracted from T cells, modifying the amplified polynucleotides such that they are suitable for incorporation into a recombinant vector, and incorporating the polynucleotide sequences encoding at least TCR ⁇ and ⁇ chain coding sequences into a recombinant expression vector. This is performed using an ordered series of steps that are described above. Primers of this disclosure are used in general in a cloning scheme, non-limiting representations of which is provided in Figures 1 and 13 .
- each of the primer sequences of this disclosure can exclude the sequence AAGGATCCGAATTCCTGCAGG (SEQ ID NO:105), and can exclude the sequence TGGAGGAGAACCCTGGACCT (SEQ ID NO:106), and can exclude these sequences from being present at the 5' end, 3' end, or at any other position in the primer sequences.
- Primers of this disclosure, such as the TCR Variable Beta primers of Table 1 can each comprise the sequence CGGCCGCCACC (SEQ ID NO:107), which may be the 5' terminal end functions as a tag in the PCR. This sequence can include ATG, which is the initiation codon for TCR ⁇ chain, at the 3' terminal end.
- Primers of this disclosure, such as the TCR Variable Alpha primers in Table 1 can each comprise at the sequence AACCCCGGTCCC (SEQ ID NO:108), which may be at the 5' terminal end.
- Complementary DNA can be synthesized from total RNA or mRNA of T cells using a reverse transcriptase and an oligo dT primer. Other primers such as random hexamer and TCR gene-specific primers can be used to prime reverse transcription.
- second strand cDNA is synthesized using combinations of primers described in Table 1. In particular, a combination of 45 and 49 forward primers containing the ATG initiation codon were designed to amplify any TCR with known V ⁇ and V ⁇ segments, respectively.
- TCR V ⁇ -specinc primers (those beginning with primer name “HTTCR#C” in Table 1) are flanked with an incomplete NotI-restriction site and the Kozak consensus sequence before initiation codon (CGGCCGCCACC(ATG)) (SEQ ID NO:109).
- TCR V ⁇ -specific HTTCR#F primers (those beginning with primer name “HTTCR#F” in Table 1) are flanked with a part of 2A sequence (AACCCCGGTCCC (ATG)) (SEQ ID NO:110) before the initiation codon. These flanked sequences function as tags in the PCR amplification process, a non-limiting illustration of which is provided in Figure 1 , Step 4.
- variable regions for TCR ⁇ and ⁇ chains are amplified by PCR using common primer sets, for example, HTTCR#A and HTTCR#B for V ⁇ and HTTCR#D and HTTCR#E for V ⁇ .
- common primer sets for example, HTTCR#A and HTTCR#B for V ⁇ and HTTCR#D and HTTCR#E for V ⁇ .
- FIG 2A and Figure 14 show one non-limiting example of TCR V ⁇ and V ⁇ PCR amplification from T-cell clones through procedures described in Figure 1 and Figure 13 .
- the second-strand cDNA synthesis and PCR reactions in Figure 1 (and Figure 13 ), Step 2 and Step 4 can be combined while Step 3 can be omitted.
- This alternative method for use with T-cell clones or single T-cells is outlined in Figure 15 . This method is preferred if the sample comprises T-cell clones or single T-cells, where different amplification efficiency by multiplexed primers is not a problem, but does not work with oligoclonal T-cell samples.
- Step 5 comprises assembly with constant fragments and cloning into a plasmid.
- the TCR ⁇ chain constant region + 2A sequence fusion fragment is amplified from a stocked template containing the fusion gene depicted in Figure 12 . This fragment overlaps with ⁇ and ⁇ chain variable region fragments at C ⁇ and 2A sites, respectively.
- This constant region fragment can contain an artificial Cysteine modification, which enhances paring with Cysteine-modified TCR ⁇ chain by forming a disulfide-bond, but those skilled in the art will recognize given the benefit of this disclosure that the constant region may be an unmodified fragment, or it may comprise any other modification, some of which are described above. Modifications can be one or more of the following: (1) replacement by TCR constant regions from other species such as those from murine TCR, (2) addition of leucine zipper motif, (3) addition of T-cell activating domains such as intracellular domains from CD3, CD28, 4-1BB, OX-40, GITR, ICOS.
- three fragments can be fused by overlapping PCR.
- An example is shown in Figure 16A .
- three fragments are mixed and amplified using HTTCR#A and HTTCR#E primers by PCR.
- Fused fragment can be cloned into expression vector by ligation-independent cloning or related methods, or by using a DNA ligase.
- An example of assembling of three fragments by overlapping PCR is shown in Figure 17 .
- the plasmid vector in which assembled TCR ⁇ and ⁇ variable regions and C ⁇ region is cloned, contains the constant region of TCR ⁇ chain which was modified by a Cysteine, which enhances paring with the Cystein-modified TCR ⁇ chain in this example.
- Modifications of TCR ⁇ chain constant region can be one or more of the following: (1) replacement by TCR constant regions from other species such as those from murine TCR, (2) addition of leucine zipper motif, (3) addition of T-cell activating domains such as intracellular domains from CD3, CD28, 4-1BB, OX-40, GITR, ICOS.
- This TCR C ⁇ overlaps with ⁇ chain variable fragments.
- the cloning vector contains tag-sequence which overlaps with ⁇ chain variable fragment.
- the ligation product is used to transform competent cells (such as Stbl3 or NEBStable) and plated on agar plate with antibiotics.
- kits comprising combinations of these primers that are suitable for use in the rapid TCR cloning processes described herein.
- the kits can comprise one or more primers, such as mixtures of primers in any combination(s), and such mixtures can be provided in one or more separate containers.
- the primer combinations in the kit can comprise or consist of the 45 and 49 primer combinations that contain the ATG initiation codon for amplifying any TCR with known V ⁇ and V ⁇ alleles, respectively. These include the TCR V ⁇ -specific primers that begin with primer name "HTTCR#C" in Table 1 and the TCR V ⁇ -specific primers that being with "HTTCR#F" in Table 1.
- kits can comprise reagents for amplification of TCRs, and for cloning the TCRs into expression vectors.
- the kits may include printed materials that instruct a user as to how to clone TCRs from samples of TCR-expressing cells.
- the disclosure includes the following sequence: NxGCGGCCGCCACCATG (Nx represents 0-50) (SEQ ID NO:111), which can be used for instance as an alternative to HT-TCR#A.
- Nx in this sequence represents any nucleotide sequences of up to 50 nts long that could be included in the primers, depending on the cloning method, such as to facilitate use of restriction enzymes, and/or ligation-independent cloning including but not necessarily limited to Gibson assembly, InFusion cloning, NEBuilder cloning, and the like.
- FIG. 1A A schematic TCR-expressing cassette designed for construction of retroviral vectors as discussed above is shown in Fig. 1A .
- TCR ⁇ and ⁇ chains were genetically connected via the P2A translational-skipping site J. Matsuzaki, et al. Sci. Rep. 5, 14896 (2015 ); N. Banu, et al. Sci. Rep. 4, 4166 (2014 )).
- the start codon for TCR ⁇ chain was preceded by the Kozak consensus sequence (GCCACC) for efficient translation.
- TCR-expressing cassette the TCR ⁇ and ⁇ chain variable (V ⁇ /V ⁇ ), joining (J ⁇ /J ⁇ ) and the TCR ⁇ chain diverse (D ⁇ ) regions that are critical for antigen recognition are required to be obtained from antigen-specific T cells.
- the constant regions can be prepared as stocked fragments that contain artificial modifications such as cysteine modification and fusion to the P2A site (a suitable procedure for making such a constant region is illustrated in Figure 16C ).
- the TCR ⁇ chain constant region can be included in the destination plasmid vector to reduce the number of fragments to be assembled.
- a destination retroviral expression plasmid was constructed as shown in Fig. 6A .
- the destination plasmid contains a TCR-expressing cassette as the stuffer fragment in which TCR C ⁇ region was modified to contain PspOMI-recognizing site (GGGCCC) for excision of the stuffer fragment together with the NotI restriction enzyme. This artificial sequence was corrected to the natural C ⁇ sequence during assembling reaction ( Fig. 6B ).
- TCR ⁇ and ⁇ chains The 5' part of TCR ⁇ and ⁇ chains, V ⁇ and V ⁇ , are highly variable. Therefore, without the knowledge of TCR sequences, a large number of multiplexed forward primers are required for PCR amplification.
- Two sets of multiplexed forward primers were designed for all known V ⁇ and V ⁇ reported in the IMGT database ( M. P. Lefranc, et al., Nucleic Acids Res. 43, D413-422 (2015 )). Sequences of primers used in this study are listed in Table 1.
- the TCR V ⁇ -specific primer set consisted of 45 primers that have the common 5' tag sequence before the start codon. Similarly, 49 V ⁇ -specific primers had another common tag sequence (the 3' region of the P2A site).
- Fig. 1B The procedures for amplification and cloning of TCR genes are depicted in Fig. 1B .
- the second-strand TCR cDNA was synthesized by a single-cycle polymerase reaction primed by multiplexed primers, thereby adding a tag sequence to 5' end of the second strand-cDNA (Step 2), followed by elimination of excess primers by Exonuclease I treatment (Step 3). Then, V ⁇ and V ⁇ fragments were amplified by PCR using tag-specific forward and TCR common region (C ⁇ or C ⁇ )-specific reverse primer pair (Step 4).
- the tag sequence for V ⁇ has a 30 nucleotides overlap with a cloning site in the destination plasmid vector, while that for V ⁇ has an overlap with a P2A-sequence.
- Cysteine-modified constant region for TCR ⁇ chain linked to P2A-sequence was PCR-amplified from the destination plasmid containing this fragment.
- Three fragments, VDJ ⁇ , C ⁇ -P2A, and VJ ⁇ , were assembled with a linearized destination retroviral plasmid vector containing the cysteine-modified C ⁇ fragment by a modified Gibson assembly using NEBuilder HiFi DNA Assembly Master Mix (Step 5).
- Using frozen stocked C ⁇ -P2A and linearized destination vector fragments assembled vectors for transform E. coli competent cells were prepared within 4 hours.
- TCR-expressing retroviral vectors from tumor antigen-specific T-cell clones
- TCR-expressing retroviral vectors for four CD8 + and five CD4 + NY-ESO-1-specific T-cell clones that have unique combinations of TCR ⁇ and ⁇ chain genes from our cell bank.
- As a control T-cell clone Jurkat T-lymphoma cell line (ATCC; TIB-152) was included. V ⁇ and V ⁇ fragments were amplified as a single band for all T-cell clones tested ( Fig. 2A ).
- the assembled TCR-expressing vectors were used to transform chemically competent E. coli. Transformed cells were spread and incubated overnight on agar plates to produce confluent colonies.
- TCR TCR-derived TCR-expressing cassettes.
- 25-35% of T cells expressed transduced TCR as determined by the increase in TCR V ⁇ subtype expression where appropriate antibodies are available ( Fig. 2C ).
- Functional expression of antigen-specific TCR ⁇ and ⁇ chain pairs was determined by MHC/peptide tetramer staining. Staining of untransduced and irrelevant TCR gene-transduced T cells was negligible.
- TCR-transduced T cells produced IFN- ⁇ and TNF- ⁇ upon co-culturing with the antigen and HLA-expressing cancer cell lines ( Fig. 2E ).
- TCR gene-transduced T cells were co-cultured with antigen-pulsed target cells or MHC class II and NY-ESO-1-coexpressing cancer cells followed by intracellular cytokine staining. As shown in Fig.
- HLA class II-restricted TCR gene-transduced T cells produced IFN- ⁇ and TNF- ⁇ upon antigen stimulation.
- TCR-cloning protocol to construct randomly paired TCR-expression library from polyclonal T-cell populations.
- TCR-expression library from polyclonal T cells from peripheral blood mononuclear cells (PBMC) of 3 healthy donors. Both TCR V ⁇ and V ⁇ were efficiently amplified from PBMC cDNA ( Fig. 3A ). Assembled plasmids were amplified in competent cells and purified from pooled colonies. The size of the library from one 50 ⁇ l vial of the competent cells was determined to be 2.8 ⁇ 0.5 ⁇ 10 5 (Mean ⁇ SD for 3 donors) by serial dilution of the transformed cells.
- TCR V ⁇ usage in TCR-expressing retroviral library was investigated by infecting retroviral particles into TCR ⁇ chain-mutated J.RT3-T3.5 (J.RT3) Jurkat T-lymphoma subline (ATCC: TIB-153). J.RT3 was transduced with retroviral library at suboptimal viral titers that transduce less than 30% of cells to minimize multi-copy transduction.
- FIG. 3B shows the relationship between the frequency of each V ⁇ subtypes in CD3 + T cells in PBMC and library-transduced J.RT3 for 3 independent libraries from different donors. Overall, V ⁇ usage in CD3 + T cells was retained in the library.
- Fig. 3C compares mean percentages of V ⁇ usage with results of statistical analyses by paired t tests. Although there were a few significant differences in the V ⁇ usage between PBMC and TCR library such as overrepresentation of V ⁇ 5.1 in the library and several minor differences, the V ⁇ usage in peripheral T cells was well reproduced in the library. These results support that the majority of TCR gene species in the polyclonal T-cell population were PCR-amplified and assembled without significant bias.
- TCR variable fragments were amplified from cDNA of frozen ovarian tumor specimens and assembled as retroviral plasmid vectors. Then, retroviral particles were produced using the bulk plasmid library.
- Polyclonally activated T cells were infected once with tumor-derived TCR-expression library at suboptimal viral titers to minimize multi-copy transduction.
- Fig. 4B significant increase in Cw*03/NY-ESO-1 tetramer-reactive CD8 + and CD4 + (which is CD8 - cells) T cells compared to untransduced T cells was observed in 2 (#2 and #3) out of 3 libraries tested albeit at low frequencies because of random pairing.
- the tetramer-stained T cells were sorted by flow-cytometry and genomic DNA that were integrated by retroviral TCR transgene were extracted.
- TCR transgene was amplified by a nested PCR from genomic DNA and was re-assembled into TCR-expressing plasmid. This secondary TCR library was used to prepare retroviral vectors to transduce primary T cells. A large fraction of the secondary TCR library-transduced T cells were reactive to the cognate antigen, as demonstrated by specific tetramer staining ( Fig. 5A ) and cytokine release against specific peptide-pulsed target cells ( Fig. 5B ).
- TCR clones in the secondary library were characterized by TCR transgene DNA fingerprinting by digestion with restriction enzymes.
- the secondary TCR library for tumor #2 was significantly enriched by a single clone (7/14 clones), while tumor #3 was enriched with 2 clones (clonotype 3A: 7/14 and clonotype 3B: 4/14).
- Transduction with the enriched TCR clone from tumor #2 and the clonotype 3A but not 3B from tumor #3 induced tetramer + T cells. Fig. 10 ).
- mice NOD/SCID/common ⁇ chain-deficient mice were inoculated subcutaneously with HLA-Cw*03 + NY-ESO-1 + A2780. On day 3 when palpable tumor was established, mice were intravenously infused with 4 ⁇ 10 6 TCR gene-transduced or untransduced T cells. While untransduced T cells showed no anti-tumor effects, TCR gene-transduced T-cell products completely eliminated established tumors in all animals ( Fig. 5D ).
- Ovarian tumor specimens were obtained at the surgery at RPCI. A part of specimen was frozen in liquid nitrogen and stored at -80°C. Remaining specimens were minced by using scissors and the gentleMACS Dissociators (Miltenyi) and mononuclear cells were isolated by the density gradient method. Tumor single cell suspension was stored in 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO) in a liquid nitrogen tank. Generation of NY-ESO-1-specific T cells was performed as described previously ( J. Matsuzaki, et al. Proc. Natl. Acad. Sci. USA 107, 7875-7880 (2010 )).
- FBS fetal bovine serum
- DMSO dimethyl sulfoxide
- peripheral or tumor-infiltrating T cells from ovarian cancer patients who had spontaneous immunity against NY-ESO-1 evidenced by the presence of serum anti-NY-ESO-1 autoantibodies, were in vitro stimulated with the NY-ESO-1 peptide(s) and cultured in the presence of 10 U/ml recombinant human (rh) IL-2 (Roche Diagnostics) and 10-20 ng/ml rhIL-7 (R&D Systems).
- Peptide-reactive T cells were identified by either staining with NY-ESO-1-specific tetramer reagents or IFN- ⁇ secretion assay reagents (Miltenyi) and were isolated by cell sorting using FACSAriaII instrument. Cells were further expanded by stimulating with phytohemagglutinin (PHA; Remel) and irradiated allogeneic PBMCs in the presence of rhIL-2 and rhIL-7.
- PHA phytohemagglutinin
- RNA from NY-ESO-1-specific T cells was obtained using TRI Reagent followed by Phenol/Chroloform extraction or the Direct-zol RNA MiniPrep kit (Zymo Research).
- Total RNA from tumor specimens (70-100 mg weight) was obtained by using tissue homogenizer in TRI Reagen followed by column purification with the Direct-zol RNA MiniPrep kit.
- Reverse transcription was performed using RevertAid First Strand cDNA Synthesis Kit using an oligo-dT primer (Thermo-Fisher).
- Primer sequences were listed in Table 1.
- cDNA was mixed with HTTCR#F for TCR ⁇ chain or HTTCR#C for TCR ⁇ chain in separate tubes in 1 ⁇ Phusion polymerase reaction master mix (Thermo-Fisher).
- Unused multiplexed primers and all single strand cDNA were destroyed by adding Exonuclease I and incubation at 37°C for 15 minutes followed by inactivation at 85°C for 15 minutes.
- Each reaction was added with a tag-specific forward and TCR constant region-specific reverse primer pair, i.e., HTTCR#D and HTTCR#E for TCR ⁇ chain and HTTCR#A and HTTCR#B for TCR ⁇ chain in 1 ⁇ Phusion polymerase reaction master mix.
- PCR was performed by 1 cycle of 98°C for 30 seconds; 2 cycles of 98°C for 10 seconds, 62°C for 30 seconds, and 72°C for 30 seconds; 30 cycles of 98°C for 10 seconds and 72°C for 60 seconds; and 1 cycle of 72°C for 2 minutes.
- the reaction was load on 1% agarose gel containing SYBR Safe DNA Gel Stain (Thermo Fisher Scientific) and electrophored at 90V for 30 minutes.
- the main band of TCR variable fragments at around 450 bp was excised under the transilluminator (Invitrogen) and DNA fragments were extracted using Zymoclean Gel DNA Recovery Kit (Zymo Research). DNA concentration was measured by absorbance at 260 nm.
- genomic DNA from TCR-transduced T cells was mixed with vector-specific primer pairs amplifying the entire TCR expressing cassette (Forward: CGAATTCCCAAACTTAAGCTTGGTACCG (SEQ ID NO:114); and Reverse: GCAGCGTATCCACATAGCGTAAAAGG (SEQ ID NO:115) in 1 ⁇ Phusion polymerase reaction mix.
- the PCR was performed by 1 cycle of 98°C for 30 seconds; 35 cycles of 98°C for 10 seconds, 71°C for 30 seconds, and 72°C for 40 seconds; and 1 cycle of 72°C for 2 minutes.
- a DNA fragment coding cysteine-modified TCR C ⁇ -P2A fusion protein was amplified by PCR from a plasmid containing this fragment and gel-purified.
- Description of the destination plasmid vector is provided in Fig. 6 .
- the destination plasmid was based on the MSCV retroviral vector with the modification of the splice acceptor site from human elongation factor 1 ⁇ promoter before the TCR cloning site and contain cysteine-modified C ⁇ fragment.
- the linearized destination plasmid (50 ng), which was treated with NotI and PspOMI and gel purified, was mixed with equimolar amount of V ⁇ , C ⁇ -P2A (obtained by PCR using HTTCR#F and HTTCR#G primers from the destination plasmid), V ⁇ fragments in 10 ⁇ l 1 ⁇ NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs) and incubated at 50°C for 60 minutes.
- the assembled product was used to transform chemically competent E. coli, NEBStable, after purification by DNA Clean & Concentrator kit (Zymo Research). Transformed E. coli was spread over three 10 cm agar plates and incubated 14-16 hours at 37°C. Confluent E. coli colonies in three plates were pooled and plasmids were purified by ZymoPURE Plasmid Midiprep Kit (Zymo Research). Quality of this bulk plasmid preparation was examined by restriction enzyme treatment with NotI and PacI which excise TCR expressing cassette from the plasmid backbone, followed by electrophoresis in an agarose gel.
- plasmids obtained from pooled E. coli colonies were used to re-transform competent cells to obtain single colonies. A part of colonies were tested for DNA fingerprinting of TCR transgene by direct colony PCR using OneTaq (New England Biolabs) using a primer pair HTTCR#A and HTTCR#E and the reaction was treated with Alul or Mspl restriction enzyme (Thermo Scientific).
- Retroviral particles were produced by co-transfection of TCR-encoding transfer plasmids and pVSV-G envelope plasmids into the GP2-293 packaging cell line (Clontech) by Lipofectamine 2000 (Invitrogen-Thermo Scientific). Packaging cells were co-incubated with plasmids for 7 hours and culture medium was replaced. After 36 hours, supernatant was harvested, centrifuged for 5 minutes at 400xg for 5 minutes and immediately used for transduction of T cells.
- PBMC peripheral blood mononuclear cells
- PBMC Pre-activated PBMC (1 ⁇ 10 5 ) were harvested, counted and plated on 96-well flat-bottom plate precoated overnight with 10 ⁇ g/ml Retronecting and 5 ⁇ g/ml anti-human CD3 monoclonal antibodies (mAb) (OKT3; eBioscience) in the presence of rhIL-2, rhIL-7 and rhIL-12. Typically, 125 ⁇ l retroviral supernatant was added to transduce T cells and culture for 24 hours. Cells were expanded in the presence of rhIL-2 and rhIL-7 without rhIL-12 and used for evaluation within 7 days after transduction. Transduction of Jurkat (E6-1; ATCC) or J.RT3-T3.5 (ATCC) was performed similarly but without activating reagents and cytokines and using reduced volumes of retroviral supernatant.
- mAb anti-human CD3 monoclonal antibodies
- TCR gene-transduced T cells were washed in PBS containing 1% FBS and incubated at 37°C for 15 minutes in the presence of 6 ⁇ g/ml phycoerythrin (PE)-conjugated tetramer in 1% FBS-PBS. Cells were then stained by allophycocyanin (APC)-conjugated anti-CD4 mAb and PerCP/Cy5.5-conjugated anti-CD8 mAb (Biolegend) at 4°C for 15 minutes.
- PE phycoerythrin
- Fluorescent signals were acquired by FACSCalibur instrument and analyzed by FlowJo software.
- tetramer + T cells were sorted using FACSAria instrument.
- Genomic DNA of sorted cells was obtained using Quick-gDNA MicroPrep kit (Zymo Research).
- Target cells were NY-ESO-1-expressing melanoma cell lines (HLA-A*02 + DRB1*01 + DPB1*04 + SK-MEL-37; HLA-B*35 + SK-MEL-52; HLA-DRB1*04 + DP*04 + COLO 316 retrovirally transduced with NY-ESO-1 and CIITA genes) or NY-ESO-1-negative HLA-Cw*03 + MZ-MEL-12.
- Cw*03-restricted NY-ESO-1-specific reactivity a Cw*03-negative and NY-ESO-1-negative A2780 ovarian cancer cell line was engineered by the Sleeping Beauty transposon system.
- Cw*03 and NY-ESO-1 co-expressing transposon plasmid was constructed by inserting human elongation factor 1 ⁇ promoter followed by Cw*03-P2A-EGFP(A206K)-T2A-NY-ESO-1 expressing cassette into pT2/BH (Addgene plasmid # 26556).
- A2780 was nucleofected using the 4D-Nucleofector system (Lonza) with pCMV(CAT)T7-SB 100 (Addgene plasmid # 34879) and pT2-EF-Cw3-GFP-ESO. GFP + clones were obtained by limiting dilution.
- target cells were unpulsed or pulsed overnight with 10 ⁇ g/ml synthetic NY-ESO-1 peptide (Genscript) or 10 ⁇ g/ml recombinant NY-ESO-1 protein (Ludwig Institute for Cancer Research) and extensively washed in RPMI1640 medium. T cells were cocultured with target cells for 6 hours in the presence of GolgiStop (BD Biosciences).
- Cells were stained by fluorescein isothiocyanate (FITC)-conjugated anti-CD4 and PerCP/Cy5.5-conjugated anti-CD8 mAbs, permeabilized using BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit (BD Biosciences), and stained with PE-conjugated anti-TNF- ⁇ and APC-conjugated anti-IFN- ⁇ mAbs (BioLegend). Cells were analyzed by FACSCalibur instrument and FlowJo software.
- FITC fluorescein isothiocyanate
- FITC fluorescein isothiocyanate
- PerCP/Cy5.5-conjugated anti-CD8 mAbs permeabilized using BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit (BD Biosciences)
- PE-conjugated anti-TNF- ⁇ and APC-conjugated anti-IFN- ⁇ mAbs BioLegend
- mice (Jackson Laboratory) were bred at the Laboratory Animal Resource at RPCI. Mice were inoculated with 1 ⁇ 10 6 IFN- ⁇ -treated Cw3 + NY-ESO-1 + A2780. Therapeutic T cells were generated by retroviral transduction of the Cw*03-restricted NY-ESO-1(92-100)-specific secondary TCR library (Tumor #3). On day 3, mice received 4 ⁇ 10 6 TCR-transduced or untransduced T cells, or untreated. On days 3-5, all T cell-infused animals were intraperitoneally injected with 5 ⁇ 10 4 IL-2 (Peprotech). Tumor growth was measured every other day. Tumor volume was calculated by a formula 0.5 ⁇ (longer diameter) ⁇ (shorter diameter) 2 . Animals were sacrificed when tumor volume reached 2,000 mm 3 .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
Claims (15)
- Verfahren für das Klonieren einer Vielzahl von TCR-α- und -β-Ketten-variablen Sequenzen von T-Zell-Rezeptoren (TCRs) von einer oligoklonalen Population von T-Zellen, wobei das Verfahren Folgendes umfasst:1) Erhalten von RNA aus einer oligoklonalen Population von T-Zellen, wobei die RNA mRNA umfasst, die TCR-α- und -β-Ketten-variable Sequenzen kodiert, und Erzeugen von erster Einzelstrang-cDNA von der mRNA, wobei die erste Einzelstrang-cDNA Folgendes einschließt: einzelsträngige cDNA, die die TCR-α-Ketten kodiert, und einzelsträngige cDNA, die die TCR-β-Ketten kodiert, wobei die einzelsträngigen cDNAs unter Verwendung von reverser Transkription und Oligo-dT-Primern erzeugt werden, um eine Probe von Erststrang-cDNA, die von der mRNA amplifiziert wurde, zu erhalten;2) Teilen der Probe von 1) in erste und zweite Probe und Durchführen von Polymerasekettenreaktionen (PCR)-Reaktionen, die Folgendes umfassen:in der ersten Probe eine Zweitstrang-cDNA-Synthese, um doppelsträngige cDNA-Amplikone zu erhalten, die die TCR-β-Ketten kodieren, unter Verwendung aller folgender Primer:
HTTCR#C.1 CGGCCGCCACCATGGATACCTGGCTCGTATGCTG SEQ.-ID Nr. 3 HTTCR.#C-2 CGGCCGCCACCATGGATACCTGGCTGTATGCTGG SEQ.-ID Nr. 4 HrrCR#C-3 CGGCCGCCACCATGGGCTGCAGGCTCCT SEQ.-ID Nr. 5 HTTCR#C-4 CGGCGCCACCATGGGCTTCAGGCTCCTCT SEQ.-ID Nr. 6 HTTCR#C-5 CGGCCGCCACCATGGGCTGCAGGCTGC SEQ.-ID Nr. 7 HTTCR#C-6 CGGCCGOCACCATGGGCTCCAGGCTGCT SEQ.-ID Nr. 8 HTTCR#C-7 CGGCCGCCACCATGGGCCCTGGGCTC SEQ.-ID Nr. 9 HTTCR#C-8 CGGCCGCCACCATGGGCCCCGGGC SEQ.-ID Nr. 10 HTTCR#C-9 CGGCCGCCACCATGOGACCCAGGCTCCT SEQ.-ID Nr. 11 HTTCR#C-10 CGGCCGCCACCATGAGCATCGGGGTCCTGT SEQ.-ID Nr. 12 HTICR#C-11 CGGCCGCCACCATGAGCCTCGGGCTCCT SEQ.-ID Nr. 13 HTTCR#C-12 CGGCCGCCACCATGAGAATCAGGCTCCTGTGCTG SEQ.-ID Nr. 14 HTTCR#C-13 CGGCCGCCACCATGAGCATCAGGCTCCTGTGC SEQ.-ID Nr. 15 HTTCR#C-14 CGGCCGCCACCATGAGCATCGGCCTCCTGT SEQ.-ID Nr. 16 HTTCR#C-15 CGGCCGCCACCATGAGCATCAGCCTCCTGTGC SEQ.-ID Nr. 17 HTTCR#C-16 CGGCCGCCACCATGGGCACCAGGCTCCT SEQ.-ID Nr. 18 HTTCR#C-17 CGGCCGCCACCATGGGCACCAGTGTCCTATGT SEQ.-ID Nr. 19 HTTCR#C-18. CGGCCGCCACCATGGGCACCAGTCTCCTATGC SEQ.-ID Nr. 20 HTTCR#C-19 CGGCCGCCACCATGGGTACCAGTCTCCTATGCTGG SEQ.-ID Nr. 21 HTTCR#C.20 CGGOCGCCACCATGGGCACCAGCCTCCT SEQ.-ID Nr. 22 HTTCR#C-21 CGGCCGCCACCATGGGGACCAGCCTCCT SEQ.-ID Nr. 23 HTTCR#C-22 CGGCCGCCACCATGGCCCTGTGTCTCCTGG SEQ.-ID Nr. 24 HTTCR#C-23 CGGCCGCCACCATGGGCACGAGGCTCTTCT SEQ.-ID Nr. 25 HTTCR#C-24 CGGCCGCCACCATGGGCACCAGGCTCTTCT SEQ.-ID Nr. 26 HTTCR#C-25 CGGCCGCCACCATGTGGCCCTTTGTCTGCTGT SEQ.-ID Nr. 27 HTTCR#C-26 CGGCCGCCACCATGGCACAAGGTTGTTCTTCTATGT SEQ.-ID Nr. 28 HTTCR#C-27 CGGCCGCCACCATGAGCACCAGGCTTCTCTGC SEQ.-ID Nr. 29 HTTCR#C-28 CGGCCGCCACC ATGGGTACCAGGCTCCTCTG SEQ.-ID Nr. 30 HTTCR#C-29 CGGCCGCCACCATGGACTCCTGGACCTTCTGC SEQ.-ID Nr. 31 HTTCR#C-30 CGGCCGCCACCATGGACTCCTGGACCCTCTG SEQ.-ID Nr. 32 HTTCR#C-31 CGOCCGCCACCATGGGCTCCTGGACCCTC SEQ.-ID Nr. 33 HTTCR#C-32 CGGCCGCCACCATGGCCACCAGGCTCCT SEQ.-ID Nr. 34 HTTCR#C-33 CGGCCGCCACCATGCTTAGTCCTGACCTGCCTG SEQ.-ID Nr. 35 HTTCR#C-34 CGGCCGCCACCATGGTTTCCAGGCTTCTCAGTTTAGTG SEQ.-ID Nr. 36 HTTCR#C-35 CGGCCGCCACCATGGGTCCTGGGCTTCTCC SEQ.-ID Nr. 37 HTTCR#C-36 CGGCCGCCACCATGAGCCCAATATTCACCTGCATCA SEQ.-ID Nr. 38 HTTCR#C-37 CGGCCGCCACCATGGACACCAGAGTACTCTGCTG SEQ.-ID Nr. 39 HTTCR#C-38 CGGCCGCCACCATGAGCAACCAGGTGCTCTG SEQ.-ID Nr. 40 HTTCR#C-39 CGGCCGCCACCATGCTGCTGCTTCTGGCTGC SEQ.-ID Nr. 41 HTTCR#C-40 CGGCCGCCACCATGGCCTCCCTGCTCTTCT SEQ.-ID Nr. 42 HTTCR#C-41 CGGCCGCCACCATGACTATCAGGCTCCTCTGCTACA SEQ.-ID Nr. 43 HTTCR#C-42 CGGCCGCCACCATGGGCCCCCAGCTC SEQ.-ID Nr. 44 HTTCR#C-43 CGGCCGCCACCATGGGAATCAGGCTCCTCTGTC SEQ.-ID Nr. 45 HTTCR#C-44 CGGCCGCCACCATGCTGAGTCTTCTGCTCCTTCTC SEQ.-ID Nr. 46 HTTCR#C-45 CGGCCGCCACCATGATGCTCTGCTCTCTCCTTGC SEQ.-ID Nr. 47 in der zweiten Probe eine Zweitstrang-cDNA-Synthese, um doppelsträngige cDNA-Amplikone zu erhalten, die die TCR-α-Ketten kodieren, unter Verwendung aller folgender Primer:HTTCR#F-1 AACCCCGGTCCCATGTGGGGAGCTTTCCTTCTCTATG SEQ.-ID Nr. 50 HTTCR#F-2 AACCCCGGTCCCATGTGGGGAGTTTTCCTTCTTTATGTTTCC SEQ.-ID Nr. 51 HTTCR#F-3 AACCCCGGTCCCATGGCTTTGCAGAGCACTCTG SEQ.-ID Nr. 52 HTTCR#F-4 AACCCCGGTCCCATGGCCTCTGCACCCATCT SEQ.-ID Nr. 53 HTTCR#F-5 AACCCCGGTCCCATGAGGCAAGTGGCGAGAGT SEQ.-ID Nr. 54 HTTCR#F-6 AACCCCGGTCCCATGAAGCACATTTGCTGGATTTTCGTTCCT SEQ.-ID Nr. 55 HTTCR#F-7 AACCCCGGTCCCATGGAGTCATTCCTGGGAGGTG SEQ.-ID Nr. 56 HTTCR#F-8 AACCCCGGTCCCATGGAGTCATCCCTGGGAGG SEQ.-ID Nr. 57 HTTCR#F-9 AACCCCGGTCCCATGGAGAAGATGCGGAGACCTG SEQ.-ID Nr. 58 HTTCR#F-10 AACCCCGGTCCCATGCTCCTGTTGCTCATACCAGT SEQ.-ID Nr. 59 HTTCR#F-11 AACCCCGGTCCCATGCTCCTGCTGCTCGTCC SEQ.-ID Nr. 60 HTTCR#F-12 AACCCCGGTCCCATGCTCCTGGAGCTTATCCCAC SEQ.-ID Nr. 61 HTTCR#F-13 AACCCCGGTCCCATGAATTCTTCTCTAGGACCAGCGATT SEQ.-ID Nr. 62 HTTCR#F-14 SEQ.-ID Nr. 63 HTTCR#F-15 AACCCCGGTCCCATGAAAAAGCATCTGACGACCTTCTTGG SEQ.-ID Nr. 64 HTTCR#F-16 SEQ.-ID Nr. 65 HTTCR#F-17 SEQ.-ID Nr. 66 HTTCR#F-18 SEQ.-ID Nr. 67 HTTCR#F-19 SEQ.-ID Nr. 68 HTTCR#F-20 SEQ.-ID Nr. 69 HITCR#F-21 SEQ.-ID Nr. 70 HTTCR#F-22 AACCCCGGTCCATGTCACTTTCTAGCCTGCTGAAGG SEQ.-ID Nr. 71 HTTCR#F-23 AACCCCGGTCCCATGAAGCCCACCCTCATCTCAG SEQ.-ID Nr. 72 HTTCR#F-24 AACCCCGGTCCCATGGAAACTCTCCTGGGAGTGTC SEQ.-ID Nr. 73 HTTCR#F-25 AACCCCGGTCCCATGCTGTCTGCTTCCTGCTCA SEQ.-ID Nr. 74 HTTCR#F-26 AACCCCGGTCCCATGAACATGCTGACTGCCAGC SEQ.-ID Nr. 75 HTTCR#F-27 AACCCCGGTCCCATGGAGAAAATGTTGGAGTGTGCATTCA SEQ.-ID Nr. 76 HTTCR#F-28 AACCCCGGTCCCATGGAGACCCTCTTGGGCC SEQ.-ID Nr. 77 HTTCR#F-29 AACCCCGGTCCCATGAAGAGGATATTGGGAGCTCTGC SEQ.-ID Nr. 78 HTTCR#F-30 SEQ.-ID Nr. 79 HTTCR#F-31 AACCCCGGTCCCATGGAGAAGAATCCTTTGGCAGCC SEQ.-ID Nr. 80 HTTCR#F-32 SEQ.-ID Nr. 81 HTTCR#F-33 AACCCCGGTCCCATGAGGCTGGTGGCAAGAGTAA SEQ.-ID Nr. 82 HTTCR#F-34 AACCCCGGTCCCATGAGGTTGGTGACAAGCATTACTGTAC SEQ.-ID Nr. 83 HTTCR#F-35 AACCCCGGTCCCATGAAGTTGGTGACAAGCATTACTGTACTC SEQ.-ID Nr. 84 HTTCR#F-36 AACCCCGGTCCCATGGTCCTGAAATTCTCCGTGTCC SEQ.-ID Nr. 85 HTTCR#F-37 AACCCCGGTCCCATGGCCATGCTCCTGGG SEQ.-ID Nr. 86 HTTCR#F-38 AACCCCGGTCCCATGGAGACTCTCCTGAAAGTGCTTTC SEQ.-ID Nr. 87 HTTCR#F-39 AACCCCGGTCCCATGGAGACTCTCCTCAAAGTGCC SEQ.-ID Nr. 88 HTTCR#F-40 AACCCCGGTCCCATGGAGACTGTTCTGCAAGTACTCC SEQ.-ID Nr. 89 HTTCR#F-41 SEQ.-ID Nr. 90 HTTC#F-42 AACCCCGGTCCCATGATGAAGTGTCCGCAGGCT SEQ.-ID Nr. 91 HTTCR#F-43 AACCCCGGTCCCATGATGAAGTGTCCACAGGCTTTACT SEQ.-ID Nr. 92 HTTCR#F-44 AACCCCGGTCCCATGACACGAGTTAGCTTGCTGTG SEQ.-ID Nr. 93 HTTCR#F-45 AACCCCGGTCOCATGACACCAGTTAGCTTGCTGTG SEQ.-ID Nr. 94 HTTCR#F-46 AACCCCGGTCCCATGGCATGCCCTGGCTT SEQ.-ID Nr. 95 HTTCR#F-47 AACCCCGGTCCCATGAAGAAGCTACTAGCAATGATTCTGTGG SEQ.-ID Nr. 96 HTTCR#F-48 SEQ.-ID Nr. 97 HTTCR#F-49 AACCCCGGTCCCATGGTGAAGATCCGGCAATTTTTGTTG SEQ.-ID Nr. 98 3) Inkubieren der ersten und zweiten Probe mit einer Exonuklease für eine Zeitdauer, die ausreicht, um Primer, die nicht in die Amplikone eingebaut wurden, und einzelsträngige cDNA, falls sie vorliegt, abzubauen, und anschließend Inaktivieren der Exonuklease unter Verwendung einer Wärmebehandlung;4) Durchführen in der ersten Probe einer PCR-Amplifikation der Amplikone, die die TCR-β-Ketten kodieren, unter Verwendung des Tag-spezifischen Primers HTTCR#A - ACTTAAGCTTGGTACCGAGCTCGGATCTGCGGCCGCCACCATG (SEQ.-ID Nr. 1) und Primers HTTCR#B - CTCAAACACAGCGACCTCGGGTGGGAACAC (SEQ.-ID Nr. 2), um Amplikone zu erhalten, die die TCR-β-Ketten kodieren, wobei die Amplikone, die die TCR-β-Ketten kodieren, weiter eine Restriktionsendonuklease-Erkennungsstelle, eine Kozak-Sequenz und eine die Translation initiierende ATG-Sequenz umfassen;
Durchführen in der zweiten Probe einer PCR-Amplifikation der Amplikone, die die TCR-α-Ketten kodieren, unter Verwendung des Tag-spezifischen Primers HTTCR#D - GGAGACGTGGAAGAAAACCCCGGTCCCATG (SEQ.-ID Nr. 48) und HT-TCR#E - AGGCAGACAGACTTGTCACTGGATTTAGAG (SEQ.-ID Nr. 49), um Amplikone zu erhalten, die die TCR-α-Ketten kodieren, wobei die Amplikone, die die TCR-α-Ketten umfassen, weiter eine P2A-Sequenz und eine initiierende ATG-Sequenz umfassen; und5) Zusammenbauen der Amplikone, die die TCR-β-Ketten und die TCR-α-Ketten kodieren, von 4) zu DNA-Vektoren, um eine Vielzahl von DNA-Vektoren bereitzustellen, wobei jeder DNA-Segmente umfasst, die nur eine der TCR-β-Ketten und nur eine der TCR-α-Ketten kodieren, wobei die Vektoren ein Cβ-2A-Fusionssegment zwischen Segmenten, die die TCR-β-Kette und die TCR-α-Kette kodieren, umfassen, wodurch eine Vielzahl von DNA-Vektoren bereitgestellt wird, wobei jeder Vektor in der Vielzahl nur eine einzige TCR-β-Kette und eine einzige TCR-α-Kette von den TCRs aus der oligoklonalen Population von T-Zellen kodiert. - Verfahren nach Anspruch 1, wobei die oligoklonale Population von T-Zellen von einem Krebstumor erhalten wird.
- Verfahren nach Anspruch 2, wobei der Tumor Folgendes umfasst: Blasen-, Gehirn-, Brust-, Eierstock-, Lungen-, Nieren-, Dickdarm-, Magen-, Bauchspeicheldrüsen-, Prostata- oder Leberkrebs, Myelom, ein Sarkom, einen Tumor, der durch Leukämie gebildet wird, Lymphom oder ein Melanom, und/oder wobei der Tumor Krebszellen umfasst, die immunogene Tumorantigene exprimieren, die mindestens eines von Folgenden umfassen: NY-ESO-1, WT1, MUC1, LMP2, HPV E6 und E7, EGFRvIII, HER2/neu, MAGE-A3, p53, NY-ESO-1, PSMA, GD2, CEA, MalanA/MART1, mutiertes Ras, gp100, Proteinase 3, bcr-abl, Tyrosinase, Survivin, PSA, hTERT, MAGE-A1, MAGE-A4, MAGE-C1, MAGE-C2, PLAC1, Sp17, TRP-2, Cyclin B1, Mesothelin, Folat-Rezeptor Alpha und patientenspezifische Neoantigene.
- Verfahren nach Anspruch 2, wobei die DNA-Vektoren von 5) die TCR-α- und die TCR-β-Ketten in Lymphozyten exprimieren können, sodass die Lymphozyten Antigenspezifität gegen ein Antigen zeigen, das von dem Krebstumor exprimiert wird.
- Verfahren nach Anspruch 2, das Folgendes umfasst: Einführen in Lymphozyten von mindestens einem der DNA-Vektoren von 5) und Ermöglichen der Expression der TCR-β-Kette und der TCR-α-Kette, die von dem mindestens einen Vektor kodiert werden, sodass die Lymphozyten einen funktionellen TCR exprimieren, der die TCR-β-Kette und die TCR-α-Kette umfasst.
- Verfahren nach Anspruch 2, das Folgendes umfasst: Einführen in Lymphozyten von mindestens einem der DNA-Vektoren von 5), Ermöglichen der Expression der TCR-β-Kette und der TCR-α-Kette, die von dem mindestens einen Vektor kodiert werden, und anschließendes Aussetzen der Lymphozyten, die den mindestens einen DNA-Vektor umfassen, gegenüber Krebszellen der gleichen Krebsart wie der Krebstumor und Bestimmen, ob die Lymphozyten Antigenspezifität gegen ein Antigen zeigen oder nicht, das von den Krebszellen exprimiert wird.
- Verfahren nach Anspruch 6, das das Bestimmen der Lymphozyten umfasst, die Antigenspezifität gegen ein Antigen zeigen, das von den Krebszellen exprimiert wird,
wobei optional die Krebszellen Folgendes umfassen: Blasen-, Gehirn-, Brust-, Eierstock-, Lungen-, Nieren-, Dickdarm-, Magen-, Bauchspeicheldrüsen-, Prostata- oder Leberkrebszellen, Myelomzellen, Sarkomzellen, Zellen von einem Tumor, der durch Leukämie gebildet wird, Lymphom oder Zellen von einem Melanom, und/oder wobei die Krebszellen immunogene Tumorantigene exprimieren, die mindestens eines von Folgenden umfassen: NY-ESO-1, WT1, MUC1, LMP2, HPV E6 und E7, EGFRvIII, HER2/neu, MAGE-A3, p53, NY-ESO-1, PSMA, GD2, CEA, MalanA/MART1, mutiertes Ras, gp100, Proteinase 3, bcr-abl, Tyrosinase, Survivin, PSA, hTERT, MAGE-A1, MAGE-A4, MAGE-C1, MAGE-C2, PLAC1, Sp17, TRP-2, Cyclin B1, Mesothelin, Folat-Rezeptor Alpha oder ein patientenspezifisches Neoantigen. - Verfahren nach Anspruch 1, wobei mindestens einige der DNA-Vektoren in der Vielzahl von DNA-Vektoren eine TCR-β-Ketten- und TCR-α-Ketten-Kombination kodieren, die nicht von einer der T-Zellen in der oligoklonalen Population von T-Zellen exprimiert wird;
das optional weiter Folgendes umfasst: Einführen in Lymphozyten von mindestens einem der DNA-Vektoren, Ermöglichen der Expression der TCR-β-Kette und der TCR-α-Kette, die von dem mindestens einen Vektor kodiert werden, und anschließendes Aussetzen der Lymphozyten, die den mindestens einen DNA-Vektor umfassen, gegenüber Krebszellen der gleichen Krebsart wie der Krebstumor und Bestimmen, ob die Lymphozyten Antigenspezifität gegen ein Antigen zeigen oder nicht, das von den Krebszellen exprimiert wird, und optional weiter Bestimmen, ob die Lymphozyten Antigenspezifität gegen ein Antigen zeigen oder nicht, das von Nichtkrebszellen exprimiert wird. - Lymphozyt, der mindestens einen DNA-Vektor umfasst, der gemäß dem Verfahren nach Anspruch 1 für die Herstellung der Vielzahl von DNA-Vektoren hergestellt wird.
- Lymphozyt nach Anspruch 9, wobei der Lymphozyt ein CD4+-Lymphozyt oder ein CD8+-Lymphozyt ist.
- Lymphozyt nach Anspruch 10, wobei der Lymphozyt die TCR-β-Kette und die TCR-α-Kette in einem funktionellen TCR exprimiert, wobei der Lymphozyt Antigenspezifität gegen Krebs zeigt, der aus Folgenden ausgewählt ist: Blasen-, Gehirn-, Brust-, Eierstock-, Lungen-, Nieren-, Dickdarm-, Magen-, Bauchspeicheldrüsen-, Prostata- oder Leberkrebs, Myelom, einem Sarkom, einem Tumor, der durch Leukämie gebildet wird, Lymphom oder einem Melanom;
oder
wobei der Lymphozyt die TCR-β-Kette und die TCR-α-Kette, die von dem mindestens einen Vektor kodiert werden, in einem funktionellen TCR exprimiert, wobei der Lymphozyt Antigenspezifität gegen mindestens eines von Folgenden zeigt: NY-ESO-1, WT1, MUC1, LMP2, HPV E6 und E7, EGFRvIII, HER2/neu, MAGE-A3, p53, NY-ESO-1, PSMA, GD2, CEA, MalanA/MART1, mutiertes Ras, gp100, Proteinase 3, bcr-abl, Tyrosinase, Survivin, PSA, hTERT, MAGE-A1, MAGE-A4, MAGE-C1, MAGE-C2, PLAC1, Sp17, TRP-2, Cyclin B1, Mesothelin, Folat-Rezeptor Alpha oder ein patientenspezifisches Neoantigen. - Kit, der Folgendes umfasst: alle der folgenden Primer: HTTCR#A (ACTTAAGCTTGGTACCGAGCTCGGATCTGCGGCCGCCACCATG; SEQ.-ID Nr. 1) und:
HTTCR#C-1 CGGCCGCCACCATGGATACCTGGCTCGTATGCTG SEQ.-ID Nr. 3 HTTCR#C-2 CGGCCGCCACCATGGATACCTGGCTGTATGCTGG SEQ.-ID Nr. 4 HTTCR#C-3 CGGCCGCCACCATGGGCTGCAGGCTCCT SEQ.-ID Nr. 5 HTTCR#C-4 CGGCCGCCACCATGGGCTTCAGGCTCCTCT SEQ.-ID Nr. 6 HTTCR#C-5 CGGCCGCCACCATGGGCTGCAGGCTGC SEQ.-ID Nr. 7 HTTCR#C-6 CGGCCGCCACCATGGGCTCCAGGCTGCT SEQ.-ID Nr. 8 HTTCR#C-7 CGGCCGCCACCATGGGCCCTGGGCTC SEQ.-ID Nr. 9 HTTCR#C-8 CGGCCGCCACCATGGGCCCCGGGC SEQ.-ID Nr. 10 HTTCR#C-9 CGGCCGCCACCATGGGACCCAGGCTCCT SEQ.-ID Nr. 11 HTTCR#C-10 CGGCCGCCACCATGAGCATCGGGCTCCTGT SEQ.-ID Nr. 12 HTTCR#C-11 CGGCCGCCACCATGAGCCTCGGGCTCCT SEQ.-ID Nr. 13 HTTCR#C-12 CGGCCGCCACCATGAGAATCAGGCTCCTGTGCTG SEQ.-ID Nr. 14 HTTCR#C-13 CGGCCGCCACCATGAGCATCAGGCTCCTGTGC SEQ.-ID Nr. 15 HTTCR#C-14 CGGCCGCCACCATGAGCATCGTCCTCCTGT SEQ.-ID Nr. 16 HTTCR#C-15 CGGCCGCCACCATGAGCATCAGCCTCCTGTGC SEQ.-ID Nr. 17 HTTCR#C-16 CGGCCGCCACCATGGGCACCAGGCTCCT SEQ.-ID Nr. 18 HTTCR#C-17 CGGCCGCCACCATGGGCAOCAGTGTCCTATGT SEQ.-ID Nr. 19 HTTCR#C-18 CGGCCGCCACCATGGGCACCAGTCTCCTATGC SEQ.-ID Nr. 20 HTTCR#C-19 CGGCCGCCACCATGGGTACCAGTCTCCTATGCTGG SEQ.-ID Nr. 21 HTTCR#C-20 CGGCCGCCACCATCGGCACCAGCCTCCT SEQ.-ID Nr. 22 HTTCR#C-21 CGGCCGCCACCATGGGGACCAGCCTCCT SEQ.-ID Nr. 23 HTTCR#C-22 CGGCCGCCACCATGGCCCTGTGTCTCCTGG SEQ.-ID Nr. 24 HTTCR#C-23 CGGCCGCCACCATGGGCACGAGGCTCTTCT SEQ.-ID Nr. 25 HTTCR#C-24 CGGCCGCCACCATGGGCACCAGGCTCTTCT SEQ.-ID Nr. 26 HTTCR#C-25 CGGCCGCCACCATGTGGCCCTTTGTCTGCTGT SEQ.-ID Nr. 27 HTTCR#C-26 CGGCCGCCACCATGGGCACAAGGTTGTTCTTCTATGT SEQ.-ID Nr. 28 HTTCR#C-27 CGGCCGCCACCATGAGCACCAGGCTCTCTGC SEQ.-ID Nr. 29 HTTCR#C-28 CGGCCGCCACCATGGGTACCAGGCTCCTCTG SEQ.-ID Nr. 30 HTTCR#C-29 CGGCCGCCACCATGGACTCCTGGACCTTCTGC SEQ.-ID Nr. 31 HTTCR#C-30 CGGCCGCCACCATGGACTCCTGGACCCTCTG SEQ.-ID Nr. 32 HTTCR#C-31 CGGCCGCCACCATGGGCTCCTGGACCCTC SEQ.-ID Nr. 33 HTTCR#C-32 CGGCCGCCACCATGGCCACCAGGCTCCT SEQ.-ID Nr. 34 HTTCR#C-33 CGGCCGCCACCATGCTTAGTCCTGACCTGCCTG SEQ.-ID Nr. 35 HTTCR#C-34 CGGCCGCCACCATGGTTTCCAGGCTTCTCAGTTTAGTG SEQ.-ID Nr. 36 HTTCR-#C-35 CGGCCGCCACCATGGGTCCTGGGCTTCTCC SEQ.-ID Nr. 37 HTTCR#C-36 CGGCCGCCACCATGAGCCCAATATTCACCTGCATCA SEQ.-ID Nr. 38 HTTCR#C-37 CGGCCGCCACCATGGACACCAGAGTACTCTGCTG SEQ.-ID Nr. 39 HTTCR#C-38 CGGCCGCCACCATGAGCAACCAGGTGCTCTG SEQ.-ID Nr. 40 HTTCR#C-39 CGGCCGCCACCATGCTGCTGCTTCTGCTGC SEQ.-ID Nr. 41 HTTCR#C-40 CGGCCGCCACCATGGCCTCCCTGCTCTTCT SEQ.-ID Nr. 42 HTTCR#C-41 CGGCCGCCACCATGACTATCAGGCTCCTCTGCTACA SEQ.-ID Nr. 43 HTTCR#C-42 CGGCCGCCACCATGGGCCCCCAGCTC SEQ.-ID Nr. 44 HTTCR#C-43 CGGCCGCCACCATGGGAATCAGGCTCCTCTGTC SEQ.-ID Nr. 45 HTTCR#C-44 CGGCCGCCACCATGCTGAGTCTICTGCTCCTTCTC SEQ.-ID Nr. 46 HTTCR#C-45 CGGCCGCCACCATGATGCTCTGCTCTCTCCTTGC SEQ.-ID Nr. 47
und:HTTCR-#F-1 AACCGCGGTCCCATGTGGGGAGCTTTCCTTCTCTATG SEQ.-ID Nr. 50 HTTCR#F-2 SEQ.-ID Nr. 51 HTTCR#F-3 AACCCCGGTCCCATGGCTTTGCAGAGCACTCTG SEQ.-ID Nr. 52 HTTCR#F-4 AACCCCGGTCCCATGGCCTCTGCACCCATCT SEQ.-ID Nr. 53 HTTCR#F-5 AACCCCGGTCCCATGAGGCAAGTGGCGAGAGT SEQ.-ID Nr. 54 HTTCR#F-6 SEQ.-ID Nr. 55 HTTCR#F-7 AACCCCGGTCCCATGGAGTCATTCCTGGGAGGTG SEQ.-ID Nr. 56 HTTCR#F-8 AACCCCGGTCCCATGGAGTCATCCCTGGGAGG SEQ.-ID Nr. 57 HTTCR#F-9 AACCCCGGTCCCATGGAGAAGATGCGGAGACCTG SEQ.-ID Nr. 58 HTTCR#F-10 AACCCCGGTCCCATGCTCCTGTTGCTCATACCAGT SEQ.-ID Nr. 59 HTTCR#F-11 AACCCCGGTCCCATGCTCCTGCTGCTCGTCC SEQ.-ID Nr. 60 HTTCR#F-12 AACCCCGGTCCCATGCTCCTGGAGCTTATCCCAC SEQ.-ID Nr. 61 HTTCR#F-13 AACCCCGGTCCCATGAATTCTTCTCTAGGACCAGCGATT SEQ.-ID Nr. 62 HTTCR#F-14 SEQ.-ID Nr. 63 HTTCR#F-15 AACCCCGGTCCCATGAAAAAGCATCTGACGACCTTCTTGG SEQ.-ID Nr. 64 HTTCR#F-16 SEQ.-ID Nr. 65 HTTCR#F-17 SEQ.-ID Nr. 66 HTTCR#F-18 SEQ.-ID Nr. 67 HTTCR#F-19 SEQ.-ID Nr. 68 HTTCR#F-20 SEQ.-ID Nr. 69 HTTCR#F-21 SEQ.-ID Nr. 70 HTTCR#F-22 AACCCCGGTCCCATGTCACTTTCTAGCCTGCTGAAGG SEQ.-ID Nr. 71 HTTCR#F-23 AACCCCGGTCCCATGAAGCCCACCCTCATCTCAG SEQ.-ID Nr. 72 HTTCR#F-24 AACCCCGGTCCCATGGAAACTCTCCTGGGAGTGTC SEQ.-ID Nr. 73 HTTCR#F-25 AACCCCGGTCCCATGCTGTCTGCTTCCTGCTCA SEQ.-ID Nr. 74 HTTCR#F-26 AACCCCGGTCCCATGAACATGCTGACTGCCAGC SEQ.-ID Nr. 75 HTTCR#F-27 AACCCCGGTCCCATGGAGAAAATGTTGGAGTGTGCATTCA SEQ.-ID Nr. 76 HTTCR#F-28 AACCCCGGTCCCATGGAGACCCTCTTGGGCC SEQ.-ID Nr. 77 HTTCR#F-29 AACCCCGGTCCCATGAAGAGGATATTGGGAGCTCTGC SEQ.-ID Nr. 78 HTTCR#F-30 SEQ.-ID Nr. 79 HTTCR#F-31 AACCCCGGTCCCATGGAGAAGAATCCTTTGGCAGCC SEQ.-ID Nr. 80 HTTCR#F-32 SEQ.-ID Nr. 81 HTTCR#F-33 AACCCCGGTCCCATGAGGCTGGTGGCAAGAGTAA SEQ.-ID Nr. 82 HTTCR#F-34 AACCCCGGTCCCATGAGGTTGGTGACAAGCATTACTGTAC SEQ.-ID Nr. 83 HTTCR#F-35 SEQ.-ID Nr. 84 HTTCR#F-36 AACCCCGGTCCCATGGTCCTGAAATTCTCCGTGTCC SEQ.-ID Nr. 85 HTTCR#F-37 AACCCCGGTCCCATGGCCATGCTCCTGGG SEQ.-ID Nr. 86 HTTCR#F-38 AACCCCGGTCCCATGGAGACTCTCCTGAAAGTGCTTTC SEQ.-ID Nr. 87 HTTCR#F-39 AACCCCGGTCCCATGGAGACTCTCCTGAAAGTGCC SEQ.-ID Nr. 88 HTTCR#F-40 AACCCCGGTCCCATGGAGACTGTTCTGCAAGTACTCC SEQ.-ID Nr. 89 HTTCR#F-41 SEQ.-ID Nr. 90 HTTCR#F-42 AACCCCGGTCCCATGATGAAGTGTCCGCAGGCT SEQ.-ID Nr. 91 HTTCR#F-43 AACCCCGGTCCCATGATGAAGTGTCCACAGGCTTTACT SEQ.-ID Nr. 92 HTTCR#F-44 AACCCCGGTCCCATGACACGAGTTAGCTTGCTGTG SEQ.-ID Nr. 93 HTTCR#F-45 AACCCCGGTCCCATGACACCAGTTAGClTGCTGTG SEQ.-ID Nr. 94 HTTCR#F-46 AACCCCGGTCCCATGGCATGCCCTGGCTT SEQ.-ID Nr. 95 HTTCR#F-47 SEQ.-ID Nr. 96 HTTCR#F-48 SEQ.-ID Nr. 97 HTTCR#F-49 AACCCCGGTCCCATGGTGAAGATCCGGAATTTTTGTTG SEQ.-ID Nr. 98 - Kit nach Anspruch 12, der weiter einen Destinationsvektor umfasst, der eine NotI- und/oder eine PspOMI-Restriktionsendonuklease-Erkennungssequenz und ein Segment, das ein Cystein-modifiziertes Ca-Fragment kodiert, umfasst;
der optional weiter eine Notl- und/oder eine PspOMI-Restriktionsendonuklease umfasst. - Kit nach Anspruch 12, der weiter Folgendes umfasst: einen oder mehrere Puffer für die Durchführung einer Erststrang-cDNA-Synthese und/oder einer Polymerasekettenreaktion (PCR) für die Durchführung einer Zweitstrang-cDNA-Synthese;
oder
der weiter eine reverse Transkriptase und/oder eine DNA-Polymerase umfasst. - Kit nach Anspruch 12, der weiter Folgendes umfasst: einen Destinationsvektor, der eine Notl- und/oder eine PspOMI-Restriktionsendonuklease-Erkennungssequenz und ein Segment, das ein Cystein-modifiziertes Ca-Fragment kodiert, umfasst, und einen oder mehrere Puffer für die Durchführung einer Erststrang-cDNA-Synthese und einer Zweitstrang-cDNA-Synthese, eine reverse Transkriptase und eine DNA-Polymerase und eine Notl- und/oder eine PspOMI-Restriktionsendonuklease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662369321P | 2016-08-01 | 2016-08-01 | |
PCT/US2017/044920 WO2018026827A1 (en) | 2016-08-01 | 2017-08-01 | Compositions and methods for rapid cloning of t-cell receptors |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3491384A1 EP3491384A1 (de) | 2019-06-05 |
EP3491384A4 EP3491384A4 (de) | 2020-04-01 |
EP3491384B1 true EP3491384B1 (de) | 2021-06-09 |
Family
ID=61073024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17837547.3A Active EP3491384B1 (de) | 2016-08-01 | 2017-08-01 | Zusammensetzungen und verfahren zum schnellen klonen von t-zell-rezeptoren |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190183935A1 (de) |
EP (1) | EP3491384B1 (de) |
CN (1) | CN109804246B (de) |
CA (1) | CA3032418C (de) |
DK (1) | DK3491384T3 (de) |
ES (1) | ES2877820T3 (de) |
WO (1) | WO2018026827A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3577234B1 (de) * | 2017-01-31 | 2024-03-20 | Ludwig Institute For Cancer Research Ltd. | Verfahren zur sequenzierung von erweiterten immunzellrezeptoren |
CN114891779A (zh) * | 2022-03-31 | 2022-08-12 | 立凌生物制药(苏州)有限公司 | 一种克隆tcr序列的检测方法及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0024550D0 (de) * | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
WO2002092770A2 (en) * | 2001-05-14 | 2002-11-21 | Henry Hongjun Ji | Novel method for cloning variable domain sequences of immunological gene repertoire |
DK1483294T3 (da) * | 2002-03-01 | 2010-11-08 | Immunomedics Inc | Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse |
US7795242B2 (en) * | 2003-10-15 | 2010-09-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
WO2009117117A1 (en) * | 2008-03-19 | 2009-09-24 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use there of |
US8524234B2 (en) * | 2011-11-03 | 2013-09-03 | Tolera Therapeutics, Inc | Antibody for selective inhibition of T-cell responses |
WO2013148372A1 (en) * | 2012-03-30 | 2013-10-03 | President And Fellows Of Harvard College | Methods for amelioration of autoimmune disease using stem cells transduced with t cell receptors from il-10 secreting t cells |
KR102452767B1 (ko) * | 2013-05-14 | 2022-10-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (car) t-세포의 인간 적용 |
US10654907B2 (en) * | 2014-01-29 | 2020-05-19 | University Health Network | Methods and compositions for producing a cell expressing a T cell receptor |
-
2017
- 2017-08-01 ES ES17837547T patent/ES2877820T3/es active Active
- 2017-08-01 WO PCT/US2017/044920 patent/WO2018026827A1/en unknown
- 2017-08-01 DK DK17837547.3T patent/DK3491384T3/da active
- 2017-08-01 CN CN201780059967.9A patent/CN109804246B/zh active Active
- 2017-08-01 US US16/318,787 patent/US20190183935A1/en active Pending
- 2017-08-01 CA CA3032418A patent/CA3032418C/en active Active
- 2017-08-01 EP EP17837547.3A patent/EP3491384B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
US20190183935A1 (en) | 2019-06-20 |
EP3491384A4 (de) | 2020-04-01 |
ES2877820T3 (es) | 2021-11-17 |
CA3032418C (en) | 2024-02-20 |
DK3491384T3 (da) | 2021-06-28 |
CN109804246B (zh) | 2022-05-17 |
WO2018026827A1 (en) | 2018-02-08 |
CN109804246A (zh) | 2019-05-24 |
CA3032418A1 (en) | 2018-02-08 |
EP3491384A1 (de) | 2019-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019210582B2 (en) | Claudin-6-specific immunoreceptors and t cell epitopes | |
JP7194230B2 (ja) | クローディン-18.2-特異的免疫受容体およびt細胞エピトープ | |
JP6612963B2 (ja) | 腫瘍抗原を直接認識するために組換えt細胞レセプターを使用するための組成物及び方法 | |
CN106414748B (zh) | 嵌合抗原受体及制备方法 | |
WO2016177339A1 (zh) | 识别ny-eso-1抗原短肽的t细胞受体 | |
Cohen et al. | Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR | |
WO2017076308A1 (zh) | 识别ny-eso-1抗原短肽的tcr | |
KR20220079645A (ko) | Kras 돌연변이를 식별하는 t 세포 수용체 및 그 코딩서열 | |
JP2015509716A (ja) | 第二世代キメラ抗原受容体におけるcd2シグナル伝達ドメインの使用 | |
CN111315769A (zh) | 信号传导和抗原呈递双功能受体(sabr) | |
Tsuji et al. | Rapid construction of antitumor T-cell receptor vectors from frozen tumors for engineered T-cell therapy | |
Gill et al. | T cell-based gene therapy of cancer | |
EP3491384B1 (de) | Zusammensetzungen und verfahren zum schnellen klonen von t-zell-rezeptoren | |
EP4089165A1 (de) | Gentechnisch veränderte t-zelle, ihre herstellung und verwendung | |
Lorenz et al. | Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7 | |
JP6692040B2 (ja) | 成人t細胞性白血病を含むhtlv−1ウイルス感染に対する腫瘍抗原特異的t細胞 | |
US20240009235A1 (en) | T cell receptors directed against bob1 and uses thereof | |
EP4079841A1 (de) | Gentechnisch veränderte t-zelle, herstellung und verwendung davon | |
CN118541388A (zh) | 识别p53中r175h突变的t细胞受体及其应用 | |
GB2569692A (en) | T cell antigen receptor chimera | |
NZ735850B2 (en) | Claudin-18.2-specific immunoreceptors and t cell epitopes | |
Liang | Functional characterization of allorestricted T cell receptors (TCRs) with specificity for HER2/neu and FMNL1 in vitro and in vivo for potential clinical application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190301 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200227 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/10 20060101ALI20200222BHEP Ipc: G01N 33/574 20060101ALI20200222BHEP Ipc: C12N 15/12 20060101ALI20200222BHEP Ipc: G01N 33/566 20060101ALI20200222BHEP Ipc: C07K 14/725 20060101ALI20200222BHEP Ipc: C12N 5/0783 20100101ALI20200222BHEP Ipc: C12N 15/85 20060101ALI20200222BHEP Ipc: G01N 33/53 20060101AFI20200222BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210210 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1400935 Country of ref document: AT Kind code of ref document: T Effective date: 20210615 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210624 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017040143 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210909 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1400935 Country of ref document: AT Kind code of ref document: T Effective date: 20210609 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210609 Ref country code: ES Ref legal event code: FG2A Ref document number: 2877820 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210909 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211011 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017040143 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210801 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170801 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230831 Year of fee payment: 7 Ref country code: GB Payment date: 20230711 Year of fee payment: 7 Ref country code: ES Payment date: 20230918 Year of fee payment: 7 Ref country code: CH Payment date: 20230902 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230821 Year of fee payment: 7 Ref country code: DK Payment date: 20230823 Year of fee payment: 7 Ref country code: DE Payment date: 20230822 Year of fee payment: 7 Ref country code: BE Payment date: 20230822 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210609 |